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Priming, in the context of nonviral gene delivery, is the treatment of cells with a
compound prior to gene transfer that enhances transfection efficiency and/or transgene
expression. Essentially, it is the application of an adjuvant approach to gene delivery.
Effective transfection strategies may require priming to compete with the efficiency of
viral transduction in order to achieve clinically relevant efficiency and expression in vivo.
To search for priming compounds, a high throughput screen of the NIH Clinical
Collection was performed using 25kDa b-PEI, an EGFP/luciferase plasmid, and
HEK293T cells. The EGFP reporter was multiplexed with Hoechst 33342 and Resazurin
fluorescence to measure transfection efficiency, transgene expression, proliferation, and
viability of the cells in response to priming with the screened NCC compounds and PEI
transfection. The screen identified dozens of compounds and several compound classes
that appear to affect transfection through modulation of mitochondrial dysfunction in
response to the toxicity of PEI complexes. With further investigation and development,
the mechanisms by which these and other priming compounds are affecting gene transfer
can be understood and applied towards the development of efficient gene delivery
strategies.
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CHAPTER 1
Pharmacological Priming, High Throughput Screening, and Drug Repurposing, in
the Context of Nonviral Gene Delivery

1.1

Introduction

The purpose of this chapter is to provide context for the research performed for
this thesis. After a brief introduction to the various methods of gene delivery, the
primary barriers to successful nonviral gene delivery are presented. A literature review
follows, which covers nucleic acid and cationic polymer design for transfection,
pharmacological priming to enhance transfection, high throughput screening methods in
general and in the context of gene delivery, and drug repurposing considerations in the
search for new priming compounds.

1.2

Gene delivery

Gene delivery is the transfer of exogenous nucleic acids into cells to modify
cellular gene expression. Modulation of gene expression is useful for studying biological
mechanisms which genes control, and can potentially enable gene therapies for treatment
of genetic disorders. There are countless applications in medical research that depend on
the expression or silence of genes, and gene delivery methods are the tools which must be
developed to achieve these functions inside target cells.
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Sickle-cell anemia is an example of a genetic disorder which can possibly be
treated by gene delivery [1-3]. In sickle-cell anemia, abnormal red blood cell morphology
is caused by mutation to the beta chain structure of hemoglobin, causing hemoglobin
polymerization. Correcting this mutation by gene therapy might be possible in different
ways. One therapy might involve delivering a combination of RNA interference and
DNA plasmid encoding correct hemoglobin to hematopoietic stem cells (HSCs) for
simultaneous knockdown of faulty hemoglobin expression and expression of functional
hemoglobin. Other methods might involve the correction (excision and replacement) of
the faulty gene in vitro of harvested autologous HSCs for re-implantation, or perhaps
involve targeted genome editing of HSCs in vivo. These gene therapies would all require
safe and effective gene delivery. Towards this end, various methods of gene delivery
have been extensively investigated.

1.2.1

Viral gene delivery

Gene delivery can be broadly classified into viral and nonviral methods. Viral
methods employ viral vectors for gene transfer, while nonviral methods accomplish gene
delivery by physical or chemical means. Viruses naturally transfer their genome into host
cells for replication, a process which can be adapted for exogenous gene transfer [4] by
insertion of the transgene into the viral genome. The viral vector then facilitates the gene
transfer into cells, a process referred to as transduction. Transduction is highly efficient
in vitro and in vivo, however, it is not trivial to modify a virus to deliver a specific gene
of interest to target cells [5], and transduction is limited by design constraints and safety
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concerns, a few of which include: size of the transgene [6], host immune response [7],
and insertional mutagenesis [8]. Insertional mutagenesis is a risk for viral methods such
as adeno-associated viral vectors, which integrate their genomes into the host genome.
Transgene length is also a design constraint for many vectors, for instance, adenoassociated vectors are limited to a transgene capacity of around 4.8kb. Also, the host
immune response to transduction can be potentially harmful to the host, and can decrease
gene transfer efficiency in initial or repeated dosing as the host develops immunity to the
viral vector [9]. Research is ongoing to develop viral vectors which overcome design
constraints and decrease safety risks, however poor results in clinical trials (including
subject fatality [10]) have prevented viral gene delivery from being utilized clinically.
Even with limitations and concerns, viral gene delivery remains the gold standard for
gene transfer efficiency against which all other gene delivery methods are measured.

1.2.2

Nonviral gene delivery

To surmount issues associated with viral gene delivery, nonviral methods of gene
delivery have been developed. Physical methods of nonviral gene delivery can be
employed which internalize the transgene into cells past the cell membrane. Bypassing
the cell membrane can be accomplished by physical methods which include
electroporation, magnetofection, ballistic insertion, ultrasound, and hydrodynamic
delivery [6]. Electroporation and ultrasound disrupt the cell membrane allowing for
nucleic acids to enter the cell, while ballistic and magnetofection methods use accelerated
particles or magnetic nanoparticles to force nucleic acids into cells. Hydrodynamic
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delivery is the highest efficiency nonviral gene delivery method [6], which involves rapid
injection of a large volume of fluid containing the nucleic acid into blood vessels. This
injection causes a transient high pressure in the local vasculature which disrupts capillary
walls and cell membranes, allowing the nucleic acids to enter parenchyma cells
surrounding the capillaries [11]. While many applications for these and other physical
methods have been developed in vitro and in vivo, clinical applications of physical
methods of gene transfer are limited because the physical disruption of cell membranes
can be damaging, and targeting gene delivery to deep tissue with these methods requires
invasive measures to provide direct access.
Chemical methods of nonviral gene delivery do not rely on physical disruption of
the cell membrane. Instead, certain chemical compounds are able to associate with
nucleic acids to form nanoparticles that facilitate the gene transfer into cells. For human
and mammalian cells, this chemical nonviral gene delivery is referred to as transfection.
Transfection compounds are generally cationic, allowing them to condense the negatively
charged nucleic acid into nanoparticle complexes which can associate with cell
membranes and be internalized by endocytosis [6]. There are several types of cationic
materials, referred to as carriers, which can associate with nucleic acids to achieve gene
delivery, including various natural and synthetic lipids and polymers. These materials
can offer advantages over physical and viral methods of nonviral gene delivery, in safety,
cost, fabrication, and flexibility in design and application. For instance nonviral carriers
are not necessarily limited like viral vectors by size of the transgene cargo or inherent
immunogenicity of the viral capsid. However, compared to viral methods, chemical
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methods of nonviral gene delivery all suffer from lower transfection efficiency, especially
in vivo [12].

1.2.3

Barriers to nonviral gene delivery

There are many barriers to successful transfection, with each step contributing to
the overall low efficiency of chemical methods of nonviral gene delivery. Systemic
barriers include serum stability, clearance, and targeting [13]. Serum stability refers to
the ability of carrier nanoparticles to protect nucleic acids from degradation by nucleases
in blood serum, avoid dissociation in serum buffer conditions, and avoid aggregation with
other complexes or serum proteins. Clearance refers to the natural removal of exogenous
material by the body, by macrophages [14] and through renal and hepatic filtration [15].
Targeting is required to specifically transfect the cells which require the gene transfer, as
non-specific transfection will decrease transfection efficiency at the target cells and could
have unintended consequences.
At the cellular level, the barriers to efficient transfection include internalization,
endosomal escape, nuclear transport, nuclear import, and transcriptional and translational
regulation [13] (illustrated in Figure 1.1 below). The carrier complexes need to be able to
associate with the cell membrane and be internalized by various endocytosis pathways in
order to enter the cell. The complexes then need to escape the endosome to avoid
degradation in a lysosome. Escape into the cytosol followed by unpacking of the
complexes is sufficient for RNA delivery, as RNA function is achieved in the cytoplasm,
though nucleases in the cytoplasm will degrade the delivered RNA. Transgenes encoded
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into DNA require transport into the nucleus for the DNA to be transcribed for
downstream expression through translation of mRNA to protein and protein folding.
However, diffusion is not sufficient to carry the DNA through the cytoplasm to and into
the nucleus, requiring active transport and import mechanisms [16]. At each step in the
gene delivery process, there is enzymatic degradation of the delivered nucleic acids. The
rate limiting barriers and degradation in the transfection process combine to result in the
overall low efficiency of chemical methods of nonviral gene delivery.

Figure 1.1 Illustration of the cellular barriers to chemical nonviral gene delivery:
internalization, endosomal escape, nuclear transport and import, and transcriptional and
translational regulation.

1.3

Nucleic acid design for nonviral gene delivery

The exogenous nucleic acids delivered to cells can be designed and modified to
improve the gene transfer efficiency and effectiveness of the gene expression or
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silencing. Certain properties can be tuned to increase their effectiveness while other
properties can be optimized to aid in overcoming cellular barriers. The tunable design
parameters depend on the intended application, with the nucleic acid being single or
double stranded DNA or RNA. For gene silencing, interfering RNAs or oligonucleotides
are used, while for transgene expression, plasmid DNAs is suitable.
Targeted reduction in expression of a gene can be accomplished through RNA
interference (RNAi) or oligonucleotides. Oligonucleotides are single stranded nucleic
acids that can bind complementary mRNA sequences and prevent their expression
through degradation by RNase H or steric blocking of translation [17], while RNAi
involves short sequences of RNA which bind and degrade target mRNA through the
RNA-induced silencing complexes (RISCs) [17]. It is thought that endogenous RNAi
plays roles in both gene regulation and in defense against viruses and transposons [18].
The interfering RNA in RNAi are generally approximately twenty base pairs in length,
double stranded in the case of small interfering RNA (siRNA) or single stranded in the
case of micro-RNA (miRNA) [17-19]. Beyond internalization and endosomal escape,
the primary determinants of gene silencing effectiveness by oligonucleotides and RNAi
are the specific nucleic acid sequence and the delivered nucleic acid’s degradation rate,
for which chemical modifications can be made to enhance their silencing activity and
specificity, and improve nuclease degradation resistance [17, 19].
An advantage of RNAi and oligonucleotide nucleic acid delivery for gene
silencing over nucleic acid delivery for transgene expression is that RNAi and
oligonucleotides do not require translocation through the crowded cytoplasm to the
nucleus and nuclear import, as plasmid DNA (pDNA) does. These requirements are
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additional barriers to efficient transfection that must be overcome to achieve successful
transgene expression. After endosomal escape, pDNA can remain complexed or unpack
from the nanoparticles. Depending on the carrier material, both packed and unpacked
pDNA have been observed in the nuclei of transfected cells [20]. The transport of pDNA
to the nucleus is not by passive diffusion, but through active transport along cytoskeletal
elements [21, 22].
Size and sequence of the pDNA influence the rate of transport and import into the
nucleus, degradation, and transgene expression. Size of the pDNA has been shown to
affect overall transfection efficiency and transgene expression, with pDNA of shorter
length being more effective, however it is uncertain whether this is due to more efficient
nuclear transport and import [23]. pDNA sequence has also been shown to affect coiling
structure of the nucleic acid, with supercoiled pDNA being optimum for transfection
[23]. Bacterial elements in the pDNA sequence can also cause an immune response
within the cell. For instance, un-methylated CPG sequences are common in bacterial
genomes, but not in mammalian DNA [24]. Toll-like receptors (TLRs) recognize
bacterial elements like CPG sequences in pDNA and evoke an immune response at the
cellular level that prevents sustained transgene expression by silencing of the transgene
on the pDNA or elimination of the transfected cell [24]. To avoid this, CPG sequences
can be minimized in plasmid design either by removal or methylation. For instance,
“minicircles”, plasmids which don’t contain a bacterial origin or antibiotic resistance
cassettes, can be used to remove all bacterial elements from the plasmid for more
sustained expression of the transgene [24].
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pDNA sequence has also been shown to influence the rate of active transport to
the nucleus and nuclear import. Transcription factor binding sites on pDNA promoter
and enhancer regions have been implicated in protein-DNA interactions, between
transcription factors and pDNA, that shuttle pDNA within the cytoplasm along
microtubules [16]. The nucleotide sequences that bind pDNA to transcription factors for
transport are referred to as DNA targeting sequences (DTS) [16]. Transcription factors
which translocate to the nucleus from the cytoplasm have nuclear localization signals
(NLS) in their peptide sequence that facilitate import of transcription factors into the
nucleus by importin proteins through Ran nuclear transport protein and the nuclear pore
complex [16]. This nuclear import of transcription factors that possess NLS and are
capable of binding pDNA at DTS may be the means by which pDNA enter the nucleus.
Both cytomegalovirus (CMV) promoter and simian virus 40 (SV40) enhancer regions are
known DTS that are commonly incorporated into plasmid designs and mediate nuclear
transport and import through transcription factor binding in the cytoplasm followed by
active transport along microtubules to the nucleus [16]. Though strong promoter regions
in pDNA can compensate for low nuclear plasmid count [25], rendering optimizations of
pDNA of limited value in vitro, low internalization rates in vivo will require such
optimization in any nonviral gene delivery strategy which hopes to match viral
transduction efficiencies and achieve sustained transgene expression.
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1.4

Polyethylenimine carrier design in nonviral gene delivery

In addition to the properties of the nucleic acid cargo which generally determine
the efficiency of a transfection strategy after endosomal escape, carrier properties and
optimization are the most important determinants in the efficiency of a chemical nonviral
gene delivery strategy in terms of facilitating delivery to and into cells. Nonviral gene
delivery with cationic polymers was first demonstrated with polylysine (PLL) in 1987
[6], whose structure is illustrated in Figure 1.2 below. Its cationic nature allowed for the
condensation of nucleic acids into nanoparticles which achieve gene delivery at low
efficiency [26].

Figure 1.2 Polylysine (PLL) [27]

The discovery of transfection with polyethylenimine (PEI), another cationic polymer,
followed in 1995, with PEI demonstrating the ability to successfully transfect in vitro and
in vivo in multiple cell types [28]. The chemical structure of the PEI polymer is shown in
Figure 1.3 below.
Cationic PEI also forms complexes with nucleic acids by electrostatic
interactions, condensing with nucleic acids to form nanoparticles. PEI nanoparticles
protect nucleic acids from degradation by nucleases and facilitate gene transfer into cells.
In contrast with PLL, PEI has a higher cationic charge density that enables more efficient
transfection, though at the cost of increased toxicity [6].
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Figure 1.3 Polyethylenimine (PEI) [29]

PEI chains have an amine group every three atoms along the polymer chain, with
two carbon spacing between amine groups. Substitution of secondary amines with
tertiary amine groups in a PEI chain will introduce branching into to the polymer
structure. The cationic nature of PEI arises from the protonation of the densely packed
secondary and tertiary amine groups in aqueous conditions, as amine groups are weak
bases. These positively charged ammonium groups are able to electrostatically associate
with negatively charged nucleic acids to form the transfection competent nanoparticle
complexes.
The cationic nature of PEI not only condenses nucleic acids into nanoparticles for
protection, but also allows for association of nucleic acids with the cell membrane.
Nucleic acids are negatively charged due to their phosphate groups, which are naturally
electrostatically repelled from the negative charge of the phosphate groups in the
phospholipid bilayer of the cell membrane. In order to enter the cell, the negative charge
of nucleic acids must be neutralized. Cationic PEI not only neutralizes the electrostatic
repulsion of nucleic acids with the cell membrane, the net charge of PEI complexes is
positive, achieving electrostatic attraction to the cell membrane, allowing PEI complexes
to associate with the cell membrane for endocytosis.
Endocytosis of PEI complexes occurs through clathrin and/or caveolar pathways,
depending on cell type, and differing between branched and linear PEI variants [30].
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Syndecan-dependent transport mechanisms involving filopodia have also been implicated
in the cell membrane association and internalization process of nanoparticle complexes
[31]. Endocytosis results in invagination of complexes which have associated with the
cell membrane into the cell, in vesicles called endosomes. PEI is able to escape
endosomes at a higher rate than PLL (PLL designs often incorporate modification to
include moieties such as chloroquine to enhance endosomal escape [12]), for reasons
which again relate to the high density of amine groups in the PEI structure. The exact
mechanisms of PEI endosomal escape are still debated, as it is difficult to definitively
observe events which occur in endosomes, but the combination of osmotic swelling of the
endosome from the “proton sponge” effect, polymer swelling, and polymer endosomal
membrane association and disruption, are thought to be involved [32].
The proton sponge effect is explained by the increased affinity for protons of the
amine groups in PEI under acidic conditions. Endosomal pH is approximately 5, which
increases the protonation degree of PEI to 40%, versus 20% at normal physiological
buffered pH of 7.4 [33]. The high proton affinity of PEI in the endosome causes an
influx of protons into the endosome, leading to an influx of chloride ions as well. The
overall influx of ions into the endosome causes an osmotic pressure which swells the
endosome, contributing to its rupture [32]. In addition to the proton sponge effect, the
increasingly protonated PEI experiences more and more electrostatic repulsion between
its own ammonium groups, which leads to swelling of the polymer volume that also
disrupts the endosome membrane [32]. The highly protonated and positively charged
PEI complexes also associate with the negatively charged endosome membrane causing
further disruption [34]. The combination of proton sponge endosome swelling, polymer
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swelling, and electrostatic interaction with the endosome membrane results in rupture of
the endosome which allows PEI complexes to escape into the cytosol. After endosomal
escape, pDNA unpacking decreases the impact of PEI properties on the remaining steps
in the transfection process, with the properties of the pDNA becoming the predominant
determinants of subsequent successful transgene expression, though, some intact
complexes have been observed localized in the nucleus [20], and PEI can have toxic
effects in the cell [35].

1.4.1

Inefficiency and toxicity of PEI transfection

General optimization of PEI transfection is accomplished through tuning of the
N/P ratio. N/P is the ratio of amine groups in the PEI polymer to phosphate groups in the
nucleic acid, determining the overall size and charge of the nanoparticle complexes. The
size and charge properties of these PEI nucleic acid complexes are the primary
determinants of their ability to circulate in serum, be internalized into the cell, and escape
the endosome, and thus are the primary determinants of transfection efficiency [28, 32,
36]. It should be noted that higher N/P ratios have been shown to add free PEI that do
not contribute to nanoparticle formation and instead remain free [37]. This free PEI has
been shown to enhance overall transfection efficiency, for unknown reasons. Optimized
PEI transfection achieves efficiency of 50-80% in vitro depending on cell type [32], type
of PEI, plasmid, and cell type, compared to the 100% efficiency achieved by optimized
viral transduction in vitro [38].
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PEI transfection efficiency of 50-80% in vitro could possibly translate to
clinically relevant transfection efficiency in vivo if systemic barriers to transfection in
vivo can be minimized and sustained transgene expression achieved [12]. PEI can be
functionalized with ligands that allow for targeting of specific cell types through, ligandreceptor binding, in order to increase effective transfection efficiency in vivo [32]. PEI
can also be modified with polyethylene glycol (PEG) or other moieties to form a
hydrophilic corona around the core PEI-nucleic acid nanoparticle, decreasing toxicity and
improving degradation resistance by shielding the complexes from interacting with
proteins, enzymes, and macrophages, increasing circulation time of the complexes in vivo
[32]. However, PEGylation has been shown to decrease the ability of complexes to
associate with cells and affect both the association and unpacking of the nucleic acid and
the carrier, reducing overall transfection efficiency, so improvements in circulation and
degradation resistance through PEGylation are achieved at a cost [32]. Bioresponsive
linkages of PEG in transfection complexes are being investigated as a strategy to employ
PEGylation while retaining optimized transfection efficiency, through shedding of the
PEG shield at the cell membrane, in the endosome, or in the cytoplasm [34].
Another tradeoff in PEI design relates to its toxicity. PEI has been shown to
cause mitochondrial dysfunction through disruption of the mitochondrial membrane that
can result in oxidative stress and apoptosis [39]. Paradoxically, PEI designs which are
more effectively able to overcome barriers to transfection also tend to be more toxic to
the transfected cell. For instance, high molecular weight (MW) and branched PEI
complexes have been demonstrated to transfect at higher efficiencies compared to low
MW and linear PEI complexes [40, 41], but also exhibit higher toxicity. Attempts to
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resolve this dilemma include bioresponsive linkages of low MW PEI into higher MW
PEI-based polymers that will degrade in the cell into less toxic lower MW constituents
[40].
In the context of gene therapy clinical trials up to the year 2012, PEI and cationic
polymer strategies in general have not been highly utilized in comparison to viral vectors
and physical methods of naked DNA delivery [42]. Viral vectors achieve the highest
targeted sustained gene transfer efficiency in vivo while naked DNA methods are less
efficient and effective, yet arguably have the best and most predictable safety profile.
Nonviral gene delivery strategies continue to be improved, but need to demonstrate
improved efficiency and safety profiles that are competitive with or exceed both viral and
physical methods of naked DNA gene delivery, respectively, to warrant vetting in clinical
trials.

1.5

Pharmacological priming as a tool for enhancing transfection

Constraints on carrier and nucleic acid design limit the extent to which carriers
and nucleic acids can be modified, and their properties tuned, towards higher transfection
efficiency and effectiveness in nonviral gene delivery. It may be necessary to employ
additional methods to modulate the cellular response to transfection in order to achieve
clinically relevant transfection efficiency and transgene expression in vivo. One
approach is to pharmacologically prime cells with chemical compounds before, during, or
after delivering carrier nucleic acid complexes to cells in order to improve some aspect of
the gene transfer process. This approach has been demonstrated to have merit in some
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studies which are discussed below. It appears that priming enhancement of transfection
efficiency and transgene expression can be through direct modulation of the barriers to
gene delivery, or indirect through modulation of the cellular response to transfection in
terms of toxicity and altered gene expression.

1.5.1

Priming compounds that enhance internalization and endosomal escape

Streptolysin O (SLO) is a bacterial endotoxin that forms pores in cell membranes,
permeabilizing the membrane and allowing diffusion of molecules of up to 100kDa
across and into cells [43]. With low doses of SLO treatment, toxicity to cells can be
minimized, and the pores in the cell membrane can be resealed by treatment with a low
concentration of Ca2+ ions. After permeabilization and resealing with this low dose SLO
and Ca2+ method, cells demonstrate internalization of external molecules as well as
measures of recovery to normal phenotype and cellular processes [43]. This technique
has been used in delivering both proteins [43] and nucleic acid [44] into cells in vitro.
Chloroquine is an antimalarial compound that has been demonstrated to enhance
nonviral gene delivery in transfections across several nanoparticle carrier formulations
[45]. A primary mechanism by which chloroquine priming enhances gene delivery is
through buffering of endosomes, aiding complexes in escaping the endosome and
avoiding lysosomal degradation. The buffering capability of chloroquine is attributed to
its behavior as a weak base [45], similar to the proton sponge effect seen in PEI amine
groups. The observation that chloroquine priming does not improve PEI transfection has
been part of the evidence that PEI itself buffers endosomes through the proton sponge
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effect to escape the endosomal compartment. Chloroquine priming does dramatically
enhance PLL transfection [46], which does not have the innate ability to escape the
endosome that PEI has. It has been shown through structure-function correlation studies
[45] that chloroquine may also enhance transfection efficiency through aiding in
unpacking of the nucleic acids from the carrier nanoparticle complex and possibly
electrostatically interacting with nucleic acids in a way that alters intracellular processing
or degradation.

1.5.2

Glucocorticoid priming enhances transfection

Glucocorticoid priming has been demonstrated to enhance viral and nonviral gene
delivery across multiple cell types [47-49]. Recent work has shown that human
mesenchymal stem cells (hMSCs), a primary cell type that is typically difficult to
transfect, showed increases in transfection efficiency and transgene expression of up to
10-fold across multiple donors, with dexamethasone (a synthetic glucocorticoid) priming
prior to transfection [49]. qRT-PCR of cytoplasmic and nuclear fractions isolated by
gradient centrifugation subcellular fractionation showed that glucocorticoid priming
increased total cellular and nuclear uptake of delivered plasmid in transfected cells [49].
The specific mechanisms of this enhancement remain unclear, but preliminary data
suggest that activation of cytosolic glucocorticoid receptors by glucocorticoid priming
may improve internalization, nuclear translocation, and nuclear import of complexes
[49].
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1.5.3 Genes implicated in successful gene delivery are priming targets for enhancing
transfection
In studies by Martin and Plautz et al [50-52], enhancement of transfection
efficiency and transgene expression were demonstrated by pharmacological priming with
activators and inhibitors of genes which had been identified as differentially expressed in
successfully versus unsuccessfully transfected HEK293T cells. At various time points,
fluorescence activated cell sorting (FACS) was used to sort cells which had been treated
with polymer or lipid pDNA complexes encoding for enhanced green fluorescent protein
(EGFP). Microarray analysis was performed on sorted and control cell populations to
create gene expression profiles for successfully transfected, unsuccessfully transfected,
and control cells which had not been treated with carrier pDNA complexes. Network
analysis was then performed on the gene expression profiles to determine differentially
expressed genes between the populations at each time point. Table 1.1 below shows an
abbreviated list of genes identified by these studies as being differentially expressed in
successfully versus unsuccessfully transfected HEK293T cells in PEI transfection.

Table 1.1: Differential gene expression between HEK293T cell populations sorted by
successful and unsuccessful EGFP expression (adapted from [50])
Gene

Role

RAP1A
CHORDC1
NEB
WDR78
PGAP1

Cell adhesion
Heat shock
Cytoskeletal dynamics
Lipid rafts
Lipid rafts
Cell stress pathways (NF-Κb,
JNK/SAPK)
Oxidative stress

ATF3
IREB2

Differential Expression
(fold change)
12.58
10.38
7.81
6.96
6.33
5.34
5.3
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Furthermore, pharmacological activation or inhibition of these differentially
expressed genes was shown to enhance or decrease transgene expression, demonstrating
that genomic targets can be modulated by priming to enhance nonviral gene delivery.
The results of these FACS/microarray studies also suggest that in addition to overcoming
the primary barriers to transfection, nonviral gene delivery strategies may need to
modulate the overall cellular response to transfection, including toxicity that causes cell
stress and genomic effects, to achieve higher transfection efficiency and more sustained
transgene expression.

1.6

High throughput screening of gene delivery

The examples of pharmacological priming described above suggest that priming
may be an effective means for improving transfection in vitro. Broad applicability of
transfection priming to different carriers, nucleic acids, and cell types has not been fully
established, but a next step would be to search for other compounds which might have
priming effects, a drug discovery endeavor. While drug discovery has historically been a
matter of educated trial and error, the modern medical research and pharmaceutical
industry has established high throughput screening methods to implement these searches
in higher volume to accelerate the process [53].
Broadly, high throughput screens are based on the idea that multiple treatment
conditions can be tested in parallel against a single target to determine which of the
treatments have desired effects on the target. In high throughput screens for drug
discovery, the treatments are large arrays of drug molecules in various stages of
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development tested against cellular targets for which the drugs could be further
developed. These cellular targets can be bioactive molecules such as signal transduction
receptors [54] and antibodies [55], or live cultured cells [56, 57].
An example application of high throughput screening for identification of novel
drugs is the identification of antiviral compounds. A recent study performed a high
throughput screen to identify broad spectrum antiviral molecules against zoonotic viruses
(SARS coronavirus and Ebola, Nipah, and Hendra viruses) [58]. The approach was to
search for compounds that inhibited CatL cleavage of viral glycoproteins, a process
required by SARS, Ebola, Nipa, and Hendra viruses, without inhibiting the CatL enzyme
itself (to preserve endogenous host functionality of the enzyme). Representative peptide
sequences for each virus were synthesized and labeled with both a light quencher and
light emitter for a FRET signal which reported cleavage of the peptide. The initial screen
of 5,000 small molecules revealed compounds that inhibited CatL cleavage of SARS
peptide, the top 50 of which were rescreened for broad spectrum inhibition of CatL
cleavage of Ebola, Nipa, and Hendra peptides, while minimizing inhibition of CatL
cleavage of host peptides. The screen was successful in identifying a molecule that was
an effective broad spectrum antiviral against all four zoonotic viruses.
High throughput screening methods have also been applied to genome-scale gene
expression through siRNA library screens [59] and DNA microarray screens [60]. In
DNA microarray screens, nucleic acid probe sequences representative of the entire
human genome are tested for complementary hybridization against mRNA samples to
determine any and all gene expression associated with the sample. This approach was
utilized as described in 1.5.3 to identify differentially expressed genes in the human
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genome of successfully versus unsuccessfully transfected HEK293T cells, with the
samples being the mRNA extracted from the FACS sorted cell populations [50-52].
These samples were tested in high throughput for hybridization against tens of thousands
of probes in parallel, with each probe corresponding to a unique gene in the human
genome, producing a comprehensive dataset identifying differentially expressed genes in
successful polymer and lipid mediated gene delivery, providing a holistic context for
nonviral gene delivery strategies to be developed which account for the total cellular
response to transfection.
High throughput RNAi screens with genome-scale siRNA libraries are similar to
DNA microarrays in that they examine gene expression at the genome wide level;
however siRNA screens search for genes and proteins which are involved in a process by
knocking down gene expression [59], in contrast to DNA microarrays which identify
genes that are expressed through mRNA in a tested sample. For example, a recent
genome wide siRNA high throughput screen revealed genes which are involved in
regulation of interleukin-8 secretion, revealing new information about the mechanisms
which contribute to the inflammation of the intestine in Crohn’s disease [61]. The DNA
microarray studies in 1.5.3 identified gene pathways involved in successful transfection
followed by secondary modulation of these genes pharmacologically; a similar yet
different differential gene expression screen can be performed from an RNAi silencing
approach that combines identification of genes involved in gene delivery and modulating
those identified genes directly through mRNA silencing by siRNA into one step, instead
of a two-step process which involves indirect pharmacological modulation of the gene.
This also implies that siRNA and not only pharmacological compounds are capable of
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priming effects on gene delivery, and should be considered potential candidates as
priming agents as well.
There are other ways high throughput screens can be specifically applied to the
application of gene delivery as a design tool. For example, high throughput screens have
been performed for optimization of transfection with lipid and polymer carrier complex
formulations. In these screens, different variations of a carriers design are tested in high
throughput transfection of cell arrays to reveal candidates whose design optimally
improves their efficacy in transfection. For example, a high throughput screen tested 144
variants of low MW linear and branched PEI (423-Da and 1.8kDa) biodegradably
crosslinked together with oligo-acrylate esters, under the premise that a high effective
MW PEI-based polymer can retain optimum transfection efficiency while also being
degradable to lower MW constituents to minimize toxicity [62], as has been
demonstrated previously [40]. The screen successfully identified vectors which exhibited
potency twice as high as 22-kDa linear PEI, while being less toxic.
The reporter proteins used to measure transgene expression in high throughput
screens of gene delivery can generally be assayed by colorimetric or luminescent
reactions, or fluorescence imaging. Fluorescence is easily multiplexed, allowing for
multiple fluorophores of different excitation and emission wavelengths to be imaged
simultaneously. Multiplexing multiple readouts in a screen is generally referred to as
high content screening. A recent study performed a high content screen of different PEI
formulations and was able to localize rhodamine labeled PEI within cells by fluorescence
microscope imaging, multiplexing rhodamine labeled PEI, GFP reporter protein, and
Hoechst DNA stain, and demonstrating the utility of a high content screening approach in
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the context of nonviral gene delivery [63]. Multiplexing of fluorophores allows for
multiple readouts from a single screen, allowing for simultaneous measurement of not
only transgene expression, but other measurements as well, such as cell viability and
proliferation. A similar multiplexed fluorescence readout high throughput and high
content screening approach was utilized in the research of this thesis which is presented
in Chapter 2.
Finally, to the extent of the literature search for this thesis, two high throughput
screens have been applied to the search for compounds which enhance gene delivery,
specifically priming adjuvants for delivery of oligonucleotides as well as viral
transduction. The most recent of these studies was the high throughput screen for
compounds that enhanced antisense and splice switching oligonucleotide (ASO and SSO)
delivery and activity [64]. ASO selectively degrade target mRNA in the cytoplasm,
while SSO modulate splicing of pre-mRNA in the nucleus [65]. The primary hits were 3deazapteridine analogs which, in vitro, showed enhancement of activity of both ASO and
SSO, with modest toxicity, in the low micromolar range.
The second of these high throughput screens for priming agents, was a high
throughput screen for priming of viral transduction, where siRNA and chemical
compounds were screened for priming of transduction efficiency and transgene
expression, identifying both siRNA sequences and chemical probes which prime viral
transduction [66, 67]. Priming compounds which enhanced transduction included
antioxidants, tyrosine kinase inhibitors, nucleoside analogs, alkylating agents, metal
chelators, and cell cycle arrestors [66]. The most potent siRNA sequences identified in
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enhancing transduction contained consensus sequences which were concluded to
modulate the interferon pathway response to viral infection [67].
The successful identification of priming compounds for viral transduction and
oligonucleotide delivery by high throughput screens suggests that it should be possible to
identify compounds that enhance pDNA delivery using nonviral methods by the high
throughput screening methods performed in this thesis research, described in Chapter 2.

1.7

Drug repurposing

In addition to using high throughput screening methods to search for priming
compounds, a drug repurposing approach was also taken in this thesis research to
increase the expected bioavailability and biocompatibility of potential priming candidates
identified by the screen, with the objective being to find priming compounds that are
already clinically accepted, like the glucocorticoids are [49]. For this purpose, the NIH
Clinical Collection was used [68]. This collection of 725 compounds is provided by the
NIH for drug repurposing research, and the goal of this thesis research was to identify
potential clinically approved compounds from this collection for repurposing to priming
of nonviral gene delivery. High throughput screens of the NCC have already been
performed to repurpose compounds for antiviral [69, 70], anti-cancer [71], and other
applications [72].
High throughput methods accelerate the process of drug discovery, but
pharmaceutical development costs remain high, an estimated $800,000,000 [73] to bring
a drug to market. In the specific application of drug discovery to transfection priming
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compounds, this expense may be justified in the future, if priming adjuvants become
widely adopted as an integral aspect of effective gene therapy, but presently, preliminary
research into transfection priming should seek compounds that have a low development
cost and are known to be biocompatible and bioavailable.
There are various metrics that are generally used to predict suitability of
compounds as pharmaceutical compounds. ADME (absorption, distribution, metabolism,
and excretion) is an acronym which describes some of the main processes a drug
encounters within an organism [74]. Additional considerations are toxicity and liberation,
which describes the release of drug from delivery vehicle. With respect to drug
properties, Lipinsky’s rule of five suggests guidelines that increase the chances a
compound will have desirable behavior in vivo [75]: 1) Molecular weight less than 500
Daltons. 2) Less than five hydrogen donors. 3) Less than 10 hydrogen acceptors. 4)
octanol-water partition coefficient (logP) less than five. It is not trivial to design a drug
that has a specific target effect while also optimizing these parameters and properties, one
reason for the extensive cost and time of drug development.

Figure 1.4 Drug-like properties of the NIH Clinical Collection [68]
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From Figure 1.4 shown above, the drug-like properties of NCC compounds are
already well defined and can be seen to adhere to Lapinsky’s rule of five, making the
NCC an ideal starting point for a high throughput screen to discover priming compounds
for nonviral gene delivery.

1.8

Thesis objectives

In summary of this chapter, the rationale for a high-throughput and high-content
screen of clinically approved compounds for priming of nonviral gene delivery has been
presented. Priming is an emerging tool for improving transfection outcomes, with
potential to be incorporated into overall efficient nonviral gene delivery strategies
through understanding and modulation of the barriers to transfection as well as the total
cellular response to transfection, and a high throughput fluorescence imaging screen of
the NCC is an ideal method of discovering additional priming agents. Chapter 2 will
describe and discuss in detail the design, implementation, and results of this screen, while
Chapter 3 will elaborate on future work which the screen suggests.
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CHAPTER 2
High Throughput Screening of Priming Candidates for Impact on Nonviral Gene
Delivery

2.1

Introduction

Gene delivery is the delivery of exogenous DNA into cells, and can be
accomplished by viral and nonviral methods, however viral methods have safety concerns
and design constraints [5], while nonviral methods lack efficiency [12]. Attempts to
improve nonviral gene delivery strategies have, to date, generally hinged on the careful
design of carriers and nucleic acid cargo [24, 76], however, their optimization may not
alone be sufficient to achieve clinically relevant transfection efficiency, transgene
expression, or gene silencing. This lack of efficiency may be due to a host of cellular
pathways associated with both successful and unsuccessful nonviral delivery [50, 51],
and these pathways may have more to do with the overall cellular response to being
transfected, than the ability of carrier complexes to overcome the barriers to transfection,
or the ability of delivered nucleic acids to have their desired effects. It could be possible
to further optimize carriers and nucleic acids to induce an appropriate cell response and
avoid an undesirable cell response, in addition to fulfilling their current design criteria;
however, further modifications to intricate carriers adds complexity to a challenge that is
already fairly intractable. Modulating these cellular response pathways by other means,
perhaps pharmacologically [50, 51, 77] or through substrate interactions [78, 79], may

28
decrease the design burden on the transfection complexes and allow effective nonviral
gene delivery strategies to be developed.
Pharmacological treatment of cells prior to transfection, i.e. priming, can enhance
or knockdown transfection efficiency and gene expression. For instance, pharmacological
modulation of genes found to be differentially expressed in, successfully versus
unsuccessfully transfected HEK293T cells, resulted in up to five fold increases and fivefold decreases in transfection [50, 51]. Another example of priming is work which
demonstrated that glucocorticoid priming markedly improved gene delivery to hMSCs in
vitro, a cell line which is difficult to transfect, enhancing transfection over 10-fold across
five human donors [77]. These results suggest that priming is a tool that should be
investigated for enhancement of nonviral gene delivery.
To efficiently search for compounds which may have priming effects on
transfection, an obvious starting point is to screen clinically approved compounds.
Previous clinical approval of a compound suggests acceptable biocompatibility and
bioavailability of the compound in vivo, which would be primary criteria for
incorporating priming into the design of gene delivery applications. If clinically
approved compounds can be repurposed for priming, the drug discovery and development
costs of viable priming compounds could be dramatically decreased.
For this purpose, the NIH provides the NIH Clinical Collection (NCC) [68], a set
of 725 clinically approved compounds to be screened for repurposing. Several studies
have successfully performed high throughput screens of the NCC to repurpose the drugs
for their potential antiviral [69, 70], regenerative [72], chemotherapeutic [71], and other
[80-82] properties. High throughput screening of gene delivery has been attempted,
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mostly for optimization of polymer [62, 83], lipid [84], and peptide [85] carriers. Perhaps
most relevantly to this thesis, a high throughput screen has been conducted for priming of
viral transduction with siRNA and chemical compounds [66, 67], which identified
several siRNA sequences and types of compounds (antioxidants, metal chelators,
alkylating agents, nucleoside analogs, cell cycle arrestors) to have priming effects on
viral transduction. The research in this thesis attempts a similar screen, though of
clinically approved compounds from the NCC, for priming of nonviral gene delivery,
with the goals being to identify an assortment of priming adjuvants for transfection, and
to improve our understanding of the biology of transfection through investigation of their
priming mechanisms.
The specific methods used in screening for enhancement of gene delivery can
vary, but generally, cell arrays are transfected with bolus and/or substrate mediated
delivery of DNA complexes [86]. Priming screens involve treatment of these cell arrays
with compounds for a certain amount of time before transfection with complexes
delivering plasmids encoding for common reporter genes like β-galactosidase (LacZ),
luciferase (Luc), and green fluorescent protein (GFP), which are often used as markers
for expression of co-transfected genes. Quantification of LacZ and Luc expression are
colorimetric and luminescence assays, respectively, while GFP can be quantified by
fluorescence measurement. A key benefit of using a fluorescent reporter for gene
expression is the ability to easily multiplex fluorophores, like Hoechst and propidium
iodide, for multiple readouts. Because of this, high throughput screens that utilize
fluorescent reporters are generally also high content imaging screens [63, 72, 85], which
can reveal information on cell viability, cell proliferation, cell cycle, cell morphology and
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more, depending on the fluorescent markers and image processing methods used,
valuable information to consider for assessing the various responses a cell may have to
priming and transfection in addition to overall transfection efficiency and transgene
expression.
We hypothesized that application of a high content fluorescence imaging
methodology to high throughput screening of clinical compounds for priming of nonviral
gene delivery would reveal drugs, or even classes of drugs, which modulate transfection
efficiency and/or transgene expression. We chose to use 25 kDa branched
polyethylenimine (PEI) as our polymer carrier because it achieves moderate, reliable, and
cheap transfection, with room to increase or decrease in efficiency and gene expression,
depending on the priming effect observed. Another reason was that 25 kDa branched PEI
was also tested as a transfection carrier in the previously discussed transfection gene
expression profiling experiments [50, 51], the data from which we intend to perform
network analysis upon in combination with the data from this screen.
In testing our hypothesis, we hope to validate the screen methods and demonstrate
that transfection priming is a promising undeveloped tool for improving transfection,
identifying clinical compounds and drug classes from the NCC whose priming effects
have potential to be incorporated into efficient nonviral gene delivery strategies through
understanding and modulation of the cellular response to transfection.
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2.2

Materials

2.2.1

HEK293T cells

Figure 2.1. Phase contrast microscope image of cultured HEK293T cells.

HEK293 are an existing mammalian cell line created from human embryonic
kidney cells of an aborted embryo, which were immortalized by adenovirus type 5
transformation [87]. The HEK293T variant of this cell line was further transformed to
express the simian virus 40 (SV40) T antigen, which is a viral transcription factor for
gene sequences that contain the SV40 promoter region, a reason HEK293T cells are
commonly used for both transient and stable recombinant protein expression [88].
Plasmids encoding genes with CMV and SV40 promoters are highly expressed in these
cells upon successful transfection, making them an ideal cell line for studies of nonviral
gene delivery [89].
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In this screen, HEK293T cells were cultured in Falcon T25 flasks (Fisher
Scientific) in Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies)
completed with 10% fetal bovine serum (Life Technologies), 1% Penicillin/Streptomycin
(Life Technologies), and 1% sodium pyruvate (Life Technologies). Cells were incubated
at 37 °C, 5% CO2, and passaged using 1 mM ethylenediaminetetraacetic acid in PBS
(EDTA) (SigmaAldrich) at 75%-85% confluence approximately every 48 hours, with
passage number ranging from 15 to 35 over the course of the screen.

2.2.2

pEGFPLuc plasmid

Figure 2.2. pEGFPLuc plasmid map [90].

The pEGFPLuc plasmid encodes for a fusion protein of enhanced green
fluorescent protein (EGFP) and luciferase. EGFP is a red-shifted variant of wild-type
green fluorescent protein (excitation/emission maxima at 488nm/507nm), while is an
enzyme that catalyzes a luminescent reaction of luciferin substrate [90]. Both are
common reporters for transfection efficiency, with this fusion providing a co-transfection
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marker that is measurable with both fluorescence and luminescence quantification
methods. The EGFPLuc sequence is flanked by a human cytomegalovirus (CMV)
promoter and an SV40 polyadenylation tail, with the plasmid backbone also containing
an SV40 origin [90], for expression in mammalian cells, especially those expressing
SV40 T antigen, as the HEK293T cells used in this screen do [87].
Neomycin and kanamycin resistance are also encoded in this plasmid, with a
bacterial promoter, SV40 promoter, and HSV TK polyadenylation tail, allowing for
propagation and selection in E. coli, by treatment with kanamycin, as well as selection of
stably transfected mammalian cells, by treatment with G418 (Geneticin) [90]. For this
screen, pEGFPLuc (Clontech) was propagated in E. coli, selected by kanamycin
treatment, isolated from the E. coli using Qiagen Giga Prep (Qiagen), and prepared in
endotoxin-free TE buffer at 1mg/mL, with purity assured by NanoDrop absorbance ratios
at 260/280 and 260/230 of approximately 1.8 and 2.0-2.2, respectively [91], and
subsequently stored in frozen aliquots at -20 °C. A single 1 mL aliquot was sufficient for
all transfections in this screen.

2.2.3

Polyethylenimine (PEI)

PEI is a cationic polymer carrier for nonviral gene delivery that serves as a goldstandard to which newly developed carriers are often compared, as it reliably overcomes
the primary barriers to transfection of cultured mammalian cells: internalization,
endosomal escape, and nuclear transport [92]. In this screen, the commonly utilized 25
kDa branched PEI (SigmaAldrich) variant was used, prepared at 1 mg/mL, dissolved at
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80 °C, in 0.1 M sodium bicarbonate, in ddH20, at pH 8.2. The 2 mL aliquots were frozen
and stored at -80°C, with a new aliquot thawed for use weekly and kept at 4 °C. Aliquots
were vortexed for 30 seconds before use in forming complexes with plasmid (as
described in Methods 2.3.4) for delivery to HEK293T cells.

2.2.4

NIH Clinical Collection

Restated simply, the primary objective of this screen was to identify, with high
throughput methods, existing clinical compounds that prime cultured cells for nonviral
gene delivery. The particular collection of pharmacological compounds screened was the
NCC from the NIH Small Molecule Repository [68], which is provided to researchers
endeavoring to repurpose clinically approved pharmaceutical compounds. The 725
compounds of the NCC were received in ten, 96-well plates, with 10 μL of each
compound (10 mM) in dimethyl sulfoxide (DMSO). Each plate was empty in the 16
wells of columns 1 and 12 (See Figure 2.3 below), with eight of the plates populated with
one compound per well in the 80 remaining wells, and the two other plates populated
with approximately 40 compounds. The 2 μL aliquots of each compound were prepared
in four 96-well plates per original NCC plate, and kept frozen at -20 °C to be thawed
before use.

Figure 2.3. NIH NCC 96-well plate, compounds in columns 2 through 11.
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2.2.5

Hoechst 33342 DNA stain

Hoechst 33342 fluorescent dye was used to stain cell nuclei and enable cell count
of fluorescence microscope images at low magnification and resolution. Hoechst stained
nuclei require minimal image processing to automate a cell count for each image.
Hoechst 33342 is a DNA intercalating dye with excitation/emission maxima at
355nm/465nm when bound to DNA, which is permeable to the cell membranes of live
cells, and is sufficiently non-toxic to allow for endpoint live cell imaging [93].
In addition to cell count and proliferation, Hoechst 33342 also provides
information on cell cycle and cell death processes, as Hoechst staining kinetics depend on
chromatin packing, amount of DNA in the cell (dependent on cell cycle), and
permeability of the cell and nuclear membranes [94]. The integrity of cell and nuclear
membranes is impaired in apoptotic and necrotic cells. Hoechst 33342 stock solution was
prepared from lyophilized powder (Sigma Aldrich), dissolved in ddH20 at a
concentration of 10 mg/mL, and stored at 4 °C.

Figure 2.4. Hoechst structure [95].
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2.2.6

Resazurin metabolic indicator

Resazurin is a reagent that is commonly used to measure proliferation and
viability of cultured cells. Resazurin solutions are a nonfluorescent blue, but become
reduced to pink resofurin in the presence of metabolic activity of cells, which fluoresces
with excitation/emission maxima at 530nm/590nm [96]. Unlike MTT assays, resazurin
does not require cell lysis, allowing for repeated viability measurements over time in
some applications, such as lymphocyte proliferation [97], though long term incubation
with resazurin has been shown to have some cytotoxic effects, recommending its use as
an endpoint assay [96]. Compared to WST-1 colorimetric assays (which also do not
require cell lysis) resazurin is much lower in cost, and its measurement by fluorescence
allows for multiplexing in live cell imaging applications by fluorescence plate reader
measurement. Stock resazurin solution was prepared from lyophilized resazurin sodium
salt powder (SigmaAldrich), dissolved in PBS at a concentration of 10 mg/mL, and
stored at 4 °C.

Figure 2.5. Resazurin (left) and Resofurin (right) [98].
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2.2.7

Rationale for fluorophore selection

For multiplexing applications, the excitation and emission spectra of the
fluorophores must be sufficiently separated to not have cross talk between the signals.
Figure 2.6 below shows the excitation and emission spectra for Hoechst 33342, EGFP,
and Resazurin, the fluorophores used in this screen.

Figure 2.6. Fluorescence spectra of Hoechst 33342, EGFP, and Resazurin [99]

There were several fluorescent markers that could have been used for each
measurement (in this screen, gene expression, cell enumeration, and viability), each with
different excitation and emission wavelengths. Other considerations included quantum
yield, sensitivity to photobleaching, permeability to the cell membrane, toxicity, etc.
EGFP was chosen for its convenient availability in our lab as a fusion protein with
luciferase, which adds a potential chemiluminescent measure of gene expression to the
screen. EGFP left the blue and red emission wavelengths open for cell counting and
viability dyes. Dyes that enable cell counting come in many forms, from nuclei stains to
cytoskeletal and membrane stains. Cytoskeletal and membrane stains generally require
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the fusion of fluorophores to antibodies of the proteins found in those features, while
nuclei stains naturally and specifically target and bind DNA. For this reason, the blue
nuclei stain Hoechst 33342 was chosen, as well as for its permeability to live cell
membranes. For viability measurements from the remaining red emission wavelengths,
there were several options. Higher permeability of certain DNA dyes into unhealthy cells
with compromised membranes compared to healthy cells with intact cell membranes is
one method of differentially staining cells for viability, with such dyes including
ethidium bromide and propidium iodide. Another type of viability measuring dyes is
metabolic indicators, which interact with the reducing environment of the cell to become
fluorescent, an example of which would be resazurin. One benefit of resazurin in
comparison to ethidium bromide and propidium iodide is that it is very inexpensive in its
unbranded form. One thing to note is that resazurin cannot be imaged only inside cells,
because its reduced form resofurin is also permeable to the cell membrane and does not
remain localized within cells, diffusing back out into surrounding media. This does not
preclude it from use as a measurement of cell viability though, and in the end, resazurin’s
metabolic measurement, similar to WST-1 and MTT assays, was deemed more sensitive
to potential priming toxicity than permeability of dyes to the cell membrane.
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2.3

Methods

2.3.1

Screening schedule

Figure 2.7. Screen timeline

The screen of the 725 clinically approved compounds in the ten 96-well plates of
the NIH NCC, for priming of PEI/pEGFPLuc transfection of HEK293T cells, was
accomplished over the course of one month. In brief, cells were seeded in 96-well plates,
primed 17 hours after seeding, transfected one hour after priming, and imaged (as
described below) 48 hours after transfection. For each NCC plate, four 96-well plates
w
e
r
e
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e
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total, the cell handling portion of the screen took approximately 120 hours to complete
over the one month period.

2.3.2

Seeding HEK293T cells for the screen

Each T25 flask at typical confluence (75-85%) provided enough cells to seed two
full 96 -well plates at a seeding density of 8,000 cells per well and seeding volume of 80
μL per well. With each well having a surface area of 0.32 cm2, the seeding density was
25,000 cells/cm2. This approximate seeding density was previously optimized in a
preliminary screen that assessed PEI transfection efficiency in HEK293T cells by LacZ
expression 48 hours after transfection
To passage, cells were rinsed with phosphate buffered saline (PBS) (Life
Technologies), detached from the flask surface by incubation in 400 μL of 1 mM EDTA
in PBS for five minutes at 37 °C, then diluted to a total cell suspension volume of 4.3 mL
in HEK293T media, with 1mL of this volume used for passaging to a new flask, and the
remaining approximately 3.3 mL available to seed plates for the screen.
Each well was seeded with 80 μL of diluted cell suspension, requiring a minimum
of approximately 15 mL dilute cell suspension for two full 96-well plates, however, an
excess dilute cell suspension of 25 mL was used, in an attempt minimize variation in
seeding density due to volume change as the suspension is used. At typical cell counts,
between approximately 1.5-2 mL of the cell suspension was diluted to 25 mL for the
desired 105 cells per mL concentration. This 25 mL suspension was split into four
volumes of approximately 6.25 mL, with two of these volumes being used to seed each
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plate. Before seeding, each volume was inverted to mix, then transferred to an
autoclaved fluid reservoir for an eight channel pipette, where they were then triturated to
mix further. From these well mixed suspensions, an eight channel pipette was used to
seed. Six rows were seeded with every 6.25 mL volume, at 80 μL of cell suspension per
well, to seed all wells of two 96-well plates. These plates were briefly examined under
phase contrast to ensure the seeding density was uniform, and then transferred to an
incubator (37 °C, 5% CO2) for the cells to adhere over 17 hours before priming and
transfection.

2.3.3

Priming HEK293T cells with NCC compounds 17 hours after seeding

From each stock NCC plate, four aliquot plates were made, containing 2 μL of
each compound per well at 10mM in DMSO. This screen required one aliquot plate from
each stock NCC plate to complete the screen of every compound in the collection at both
5 μM and 50 μM. These concentrations are relative to the 141 μL total liquid volume
added to the wells in seeding, priming, and transfecting. The following descriptions are of
the priming compound preparations of one aliquot plate of the NCC collection, which
were repeated for all ten of the NCC plates. To prepare the compounds from an aliquot
plate for delivery to cells, the plate was thawed for 15-30 minutes at room temperature
prior to dilution in HEK293T media, while the HEK293T media was concurrently
warmed to 37 °C in a water bath. As vehicle controls, 2 μL DMSO was added to each of
the empty wells of columns 1 and 12 of the aliquot plate (Figure 2.4 for reference). To
dilute the aliquot plate for the 50 μM priming concentrations, and equivalent 1.4%
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DMSO (v/v) in the vehicle control wells, 111.48 μL of warmed HEK293T media was
added to each well of the aliquot plate, triturating to mix well. Approximately 17 hours
after seeding two plates with HEK293T cells, 40uL of each compound of the aliquot
plate were gently delivered by eight channel pipette into corresponding wells of both
seeded plates. The priming volumes were pipetted with the tips angled to gently dispense
against the side of the wells and minimally disturb the cells in the wells. The primed
plates were then incubated for one hour at 37 °C, 5% CO2 before transfection. Priming
two plates requires 80 μL of each 50 μM compound, so there was approximately 31.5 μL
remaining of the original 113.48 μL of each compound in the aliquot plate after priming
both seeded plates. The remainder of the 50 μM concentrations in the aliquot plate was
frozen, to be thawed and diluted for priming at 5 μM within 24 to 48 hours. To prepare
the 5 μM priming concentrations, 12 μL of the thawed remainder of the 50 μM
concentrations were diluted with 108 μl of warmed HEK293T media, triturating to mix
well, before delivering 40uL of each compound to corresponding wells in two seeded
plates. The primed plates were then incubated for one hour at 37 °C, 5% CO2 before
transfection.

2.3.4

Transfection of HEK293T cells one hour after priming with NCC compounds

DNA/PEI complexes were formed in Tris-buffered saline (TBS). Previously, a
preliminary screening experiment determined that 0.17 μg of pEGFPLuc, complexed
with 0.34 μg of 25 kDa branched PEI at N/P ratio of 15, and delivered in a 21 μL TBS
volume to each well, was an optimum formulation for this screen format. For
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transfection of two full 96-well plates, this formulation amounted to four pairs of 1.5mL
microcentrifuge tubes consisting of 20.4 μL of 1 mg/mL 25 kDa branched PEI, in 471.91
μL of TBS, to be mixed into 10.2 μL of 1 mg/mL pEGFPLuc, in 728.26 μL of TBS. The
total volume ratio of DNA to PEI tubes was 60:40. To form the complexes, the PEI tubes
were pipetted into the pEGFPLuc tubes, triturated five times, vortexed for 10 seconds,
and then incubated at room temperature for 15 minutes. After the incubation, the
complexes were combined into an autoclaved fluid reservoir to be dispensed at 21 μL per
well into all wells of both plates, by eight channel pipette, after one hour of incubation
with priming compounds.

2.3.5

Staining HEK293T cells 48 hours after PEI transfection

After a 48 hour incubation following transfection, at 37 °C, 5% CO2, the primed
and transfected HEK293T plates were stained with Hoechst and Resazurin fluorescent
dyes to enable subsequent nuclei counts and viability assessments, respectively,
multiplexed with the EGFP fluorescent reporter for transgene expression. The staining
solution consisted of 38.5 μL of 10 mg/mL Hoechst 33342 stock solution, and 22 μL of
10 mg/mL Resazurin stock solution, in 22 mL of warmed Fluorobrite DMEM
(ThermoFisher). Instead of aspirating the wells before rinsing and staining, the plates
were “flicked” upside down several times over a container which caught the ejected
liquid. Flicking two plates was much faster than aspirating each well, did not noticeably
detach cells from the plate bottoms, and left small volumes of liquid in each well,
preventing bare air exposure of the cells. Plates were flicked and rinsed with 100 μL of
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PBS per well, and flicked again before 100 μL of the staining solution was added to each
well. The plates were then incubated for 30 minutes at 37 °C, 5% CO2. Care to avoid
exposure of the dyes to light was taken throughout the staining process, to prevent
photobleaching.

2.3.6

Fluorescence microscope imaging of screen plates

After incubation with the staining solution, plates were imaged using a
DMI3000B manual inverted microscope (Leica) with DFC340FX digital camera (Leica),
EL-6000 mercury halide lamp (Leica) for fluorescence excitation, and LAS software
V4.0 (Leica) for digital image viewing and capture. Filters for excitation and detection at
the EGFP and Hoechst wavelengths (488nm/509nm and 355nm/465nm, respectively)
were used to take grey scale images of their fluorescence, in addition to phase contrast
images. Images were taken with a 5x objective (HCX FL PLAN 5X/0.12), center well.
Cells were manually focused in phase contrast, with the focus unchanged for the EGFP
image, and unchanged or with minor focus adjust for the Hoechst image to bring into
focus as many nuclei as possible. Phase contrast images were captured at 473 μs
exposure (gain 1x, gamma 1.00), while EGFP and Hoechst fluorescence images were
captured at 108.6 ms exposure (gain 2.0x, gamma 1.15). Consistent fluorescence
excitation lamp intensity (second highest setting) was used for all EGFP and Hoechst
images in the screen. Keeping those settings consistent allowed for comparison of image
intensities between wells in the same plate. Using these settings was also much faster
than auto-exposure by the software, allowing for faster overall imaging times, which
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averaged to about 45 minutes per plate (acquiring phase contrast, EGFP, and Hoechst
images for every well) and 288 images per plate. Wells were imaged down each column
from row A to row H, from column 1 through column 12. Images were captured at
1600x1200 pixels in 8-bit TIFF image format. Figure 2.8 below shows plate montages of
EGFP and Hoechst fluorescence images acquired from a typical plate in the screen.

Figure 2.8. EGFP and Hoechst images acquired from a typical plate in the screen,
stitched together to form montages which resemble the 96 well plate format.

Figure 2.9(a) is a phase contrast microscope image of a typical vehicle control
well in this screen, taken with a 5x objective, center well. Figure 2.9(b,c) shows the
fluorescence microscope images of Hoechst and EGFP taken of the same well. These
fluorescence images were pseudo-colored and overlaid by merging the images into RGB
color format to provide a combined visual representation of transfection efficiency,
transgene expression, and cell count, in one image, as shown in Figure 2.9(d).
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Figure 2.9. Microscope images of a vehicle control well, in phase contrast (a) as well as
EGFP (c) and Hoechst (d) fluorescence. The fluorescence images were also pseudocolored and overlaid (d)

Initially, a primary concern was whether the cells would remain viable enough for
the length of time required to manually acquire all images of a plate outside controlled
temperature and carbon dioxide regulation. The most obvious hindrance encountered in
imaging for this length of time without environmental control was the water condensation
on the lids of the plates, which caused uneven illumination and shadows between wells,
shown in Figure 2.10 below.
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Figure 2.10. Phase contrast image montage that demonstrates shadowing due to
condensation on the plate lid.

Phase images are difficult to process with uneven illumination and shadows due
to their bright-field background illumination. To normalize these variations between all
wells would require the development of image processing algorithms beyond the current
scope of this screen, so phase images were acquired in the screening process but not
processed. There is potential for future processing of these images to reveal information
about overall cell morphological changes due to priming and transfection.
Fluorescence images did not have the same uneven background signal, and were
more easily processed for intensity and count measurements. The important acquisition
parameters were excitation intensity, detector exposure time, image location within the
well, and focus. The lamp and detector parameters were kept consistent for the entire
screen, while image location within wells was kept as consistently center of the well as
possible by, in phase contrast, aligning and centering the image area on the brightest area
of the well, which is almost always the center of the well. The cells were also brought
into focus while viewing in phase contrast.
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The nearly hour long exposure of the plate to room temperature and unregulated
CO2 did not noticeably affect the ability to capture representative images and quantify
GFP or Hoechst fluorescence. Cells were not seen to detach from the well surface. The
Fluorobrite DMEM imaging media was used due to its compatibility with live cell
imaging, lacking phenol red that could interfere with the fluorescence measurements, and
including glucose and sodium bicarbonate. The manufacturer’s website also claims a
higher signal to noise compared to PBS or other media formulations. The Fluorobrite
DMEM was used as is, without supplementing with FBS or L-glutamine. It is important
to note that imaging without temperature and carbon dioxide regulation was accepted for
this endpoint imaging of cumulative transfection efficiency, gene expression, and cell
number and viability after 48 hours of incubation post-transfection, not for more transient
and delicate processes or with the intention to return these cells to the incubator for
further culture, in which cases, environmental control would be required.

2.3.7

Fluorescence plate reader measurement

In addition to microscope imaging, EGFP, Hoecshst, and Resazurin fluorescence
was measured by a Synergy H1 plate reader (BioTek), with excitation/emission settings
of 475nm/509nm, 355nm/464nm, and 545nm/590nm, and gain settings of 100, 50, and
50, respectively. Probe height was re-calibrated for each of these measurements for each
plate by determining the probe heights that yielded maximum signal in a selected control
well, and using those setting for the entire plate. Gain and probe height were selected
such that the signal was strong enough to be detected but also not saturating the detector.
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The excitation wavelength used for EGFP was shifted away from the 488nm maximum
down to 475nm, as the plate reader required the excitation wavelength to be sufficiently
far from the emission wavelength. At the EGFP, Hoechst, and Resazurin wavelengths,
nine measurements were taken per well in a three by three array equally spaced within
the well, from which mean intensities was calculated. The plate reader was used to
quantify the amount of EGFP (transgene expression reporter), Hoechst (nuclei stain), and
Resazurin (viability measure) in every well, to measure the effects each drug had on
transfection and cell viability. Hoechst was used as nuclei marker for cell counting by
microscope image processing, but plate reader measurements were also acquired, as
normalized Hoechst intensity may indicate cell cycle and cell death processes. Figure
2.10 below shows an example of these data for a typical plate of the screen, with heat
map color shading to ease visual interpretation of the data.

Figure 2.11. Typical plate reader measurements of EGFP, Hoechst, and Resazurin
fluorescence. Darker shades indicate more intense fluorescence signal.
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2.3.8

Comparison of microscope image and plate reader measurements

For a comparison of plate reader and microscope images, see Figure 2.11 below.
The well outlined in yellow immediately stands out as having an approximately two fold
higher of EGFP than any other well in both the plate reader measurement and EGFP
images. Very low values in these measurements generally corresponded to wells having
few cells due to toxicity of the priming condition, though in some cases, like the well
outlined in red, there was very low EGFP expression with normal or high Hoechst and
Resazurin readings, indicating normal or enhanced proliferation/viability.

Figure 2.12. Comparison of plate reader and fluorescence microscope images
showing qualitative similarity in the observed fluorescence by both methods.

The primary limitation to the quantification of fluorescence through microscope
images was the limited viewing area. The culture area of a 96-well plate is pproximately
32 cm2, while at lowest magnification (5x) the image area is approximately 5.9 mm2, so
images capture approximately 18% of the well area. Cells were always more densely
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packed in the central area of the well, so there was always more than 18% of the cells in
the well in the images, up to 100%, seeming to depend on the toxicity of the priming
compound. That being said, a significant portion of each well’s cell population was
generally outside the image area. The options for measuring the fluorescence from these
cells were either taking images at multiple locations per well, or measuring with a
fluorescence plate reader in an array scan. The microscope imaging time of a full plate
with three images per well (phase contrast, EGFP, and Hoechst, center well) was already
45 minutes, so it was hard to justify adding more locations and time per well without
environmental and CO2 control, unless there was no other option. A 3x3 array scan
covers approximately 24 mm2 of the well, 75% of the well area, and about four times the
area of the microscope image.

Figure 2.13. Microscope imaging and plate reader measurement areas, demonstrating the
larger area coverage of the plate reader measurement but lower resolution.
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The plate reader was able to measure fluorescence of EGFP, Hoechst, and
Resazurin wavelengths, in 3x3 array scans per well, in approximately 15 minutes total
per plate, about three times faster than microscope imaging of phase contrast, EGFP, and
Hoechst. The primary disadvantage of a plate reader measurement is that it only reads an
array of intensities, rather than capturing a high resolution image that can be processed to
extract more information, such as total cell counts and transfected cell counts, which
were essential for normalization in this screen. For these reasons, fluorescence
microscope images and fluorescence plate reader measurements were both acquired for
each plate. Both of these measures were used in the hit selection and scoring process,
considered individually and as part of overal transfection, proliferation, and viability
scores.

2.3.9

Cell lysis

After imaging and plate reader measurements, cells were lysed for storage and
potential future measurements of the lysate luciferase content. For lysis of two full 96well plates, 22 mL of 1x Reporter Lysis buffer (RLB) was sufficient, and was prepared
by dilution of 4.4 mL of 5x Reporter Lysis Buffer (Promega) in 17.6 mL of ddH20. Each
plate was flicked and rinsed with 100 μL PBS per well, with 100 μL of 1x RLB then
delivered to each well, after which the plates were incubated at room temperature for 510 minutes before freezing and storage at -80 °C.
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2.3.10 Image processing

Macros in ImageJ (NIH), a Java based image processing program, were used to
automate the mean fluorescence intensity measurements and maxima counts for the
processing of the 11,520 images acquired over the course of the screen. For each well,
EGFP and Hoechst images were processed for average grey value, as the mean intensity
EGFP and Hoechst fluorescence measurements, while local maxima were also identified
to obtain counts of Hoechst stained nuclei and of EGFP expressing cells. See Figure 2.14
below for a representation of the image processing for each Hoechst and EGFP image for
intensity and count, and Appendix B for the ImageJ macros used for the image
processing in this screen.

Figure 2.14. Hoechst nuclei and transfected cell counting by local maxima
detection.
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Average grey values of the Hoechst and EGFP images were determined using the
“Measure” plugin in ImageJ. Figure 2.14 shows total cells and transfected cells counted
by the “Find Maxima” plugin in ImageJ. The local maxima in the Hoechst and EGFP
images were determined, point selected, and counted. The noise tolerance of the “Find
Maxima” plugin was adjusted to optimize detection and minimize misidentification of
nuclei and EGFP cells. These measurements were automated by macros in ImageJ.
All microscope images were stitched together into image arrays to ease visual
inspection of the 96 -well format, such as in Figure 2.15 below. Similar image montages
were created for every plate in the screen, for phase contrast, EGFP, Hoechst, and
pseudo-color overlay images. The processed image data were also compiled into 8x12
spreadsheet arrays, the same format as the plate reader measurements. The image array
and image data in Figure 2.15 below, are from the same plate as the plate reader data
shown in Figure 2.12, and show similar results.

Figure 2.15. Image array aside image data processed from the images.
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The yellow box outlines a well which, by visual inspection, obviously had a
relatively high amount of EGFP, reflected in the relatively high EGFP image mean
intensity measurement, but did not have a relatively high image EGFP count, implying
that the higher amount of EGFP in that well was due to an increase in EGFP expression
in transfected cells rather than a higher number of transfected cells, a useful distinction to
make when interpreting the data to explain the effects the various compounds might be
having on gene delivery. Similarly, the well outlined in red appears to have exhibited a
large knockdown of both EGFP amount and transfected cell count, while exhibiting a
high total cell count.

2.3.11 Control filtering

Data were transferred to Excel (Microsoft) and Prism (Graphpad) for data
processing and statistical analysis. As seen in figure 2.16 below, there was variation in
the Hoechst count of the transfected vehicle control wells in columns 1 and 12, which is
due to variance in the initial seeding density. Low initial seeding density in a well
increases the number of transfection complexes available per cell, increasing transfection
efficiency as well as toxicity in that well relative to other transfected vehicle controls
wells. To prevent potential unfair comparisons from control well transfection and
toxicity bias due to initial seeding density which might result in discarding true priming
candidates screened, as seen in Figure 2.16 below, transfected vehicle control wells
which had total cell counts less than 95% of the mean of the vehicles controls as a whole
for that plate were discarded from consideration for calculations of fold changes.
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Figure 2.16 Demonstration of control filtering in the hit selection process

2.3.12 Normalized fold change measurements

After filtering the controls, the image data for each well were normalized by their
associated Hoechst total cell count or transfected cell count and their fold changes
determined relative to the filtered vehicle control wells in columns one and twelve, as
seen in Figure 2.17 below. For example, the yellow outlined well was calculated to have
a fold change increase in EGFP intensity per cell of 2.2, with no increase in transfection
efficiency (% EGFP+) and a 0.7 fold decrease in cell count, while the red outlined well
displayed a fold change decrease in both EGFP intensity per cell (0.18 fold) and
percentage of cells expressing EGFP (.0003 fold), while exhibiting a fold increase in cell
count (1.12 fold).
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Figure 2.17. Normalized fold changes of EGFP measures and cell count.

2.3.13 T-test and toxicity filter of normalized fold change measurements

Data acquired for each well included: image measurements of EGFP intensity and
count, and Hoechst intensity and count, as well as plate reader measurements of EGFP,
Hoechst, and Resazurin intensities. Each compound was tested in duplicate at both 5 and
50 μM concentrations. The fold changes of each measurement for each well relative to
the filtered average vehicle control fold changes were then calculated, after which, the
duplicate fold changes for each well were then grouped for unpaired two-tailed t-tests,
assuming unequal variances, against the grouped filtered vehicle controls, to obtain a pvalue for the measurements of each compound
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Figure 2.18. p-value (top right) and Hoechst count fold-change (bottom right) versus
EGFP image intensity fold-change. It can be seen from this figure that compounds which
appear to have high fold changes are often artifacts of wells which had extremely low cell
counts.

These t-tests were not performed to assess significance, instead, the t-tests were
used as an initial filter in the hit selection process, to throw out compounds whose effect
size caused their –log(p-values) to be lower than the plate wide –log(average of p-values)
for sample wells. Figure 2.18 (top right) shows this filtering, with the compounds with –
log(p-values) less than –log(pavg) discarded from further consideration. From the red and
yellow arrows pointing at their corresponding compounds outlined in red and yellow on
the image montage, it is obvious that a slight decrease in p-value threshold might have
caused these wells to be mis-identified as false negatives, even though they clearly
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deserve further investigation simply from visual inspection. This t-test filtering was
performed for all EGFP, Hoechst, and Resazurin measurements.
After the t-test filters, the cytotoxicity filters were implemented. The first
simply eliminates compounds which had normalized Hoechst count fold change
decreases of less than 0.2, which were automatically discarded as extremely toxic,
corresponding in Figure 2.18(bottom right) to the red region, and the almost completely
empty wells seen in the images of Figure 2.18(left). From the remaining compounds, the
average Hoechst count fold change was determined, including the blue and white regions
of Figure 2.18(bottom right), from which a minimum proliferation filter was
implemented, one standard deviation below the average Hoechst count fold change of the
remaining tested compounds in the plate, shown as the blue shaded region. From the
yellow and red arrows, it can be seen that both yellow and red outlined wells survive the
toxicity filters for further consideration.

2.3.14 Scoring and hit selection

The next step in the hit selection process was to create a combined average fold
change score for transfection, proliferation, and viability measurements of each
compound tested. The transfection (EGFP) score was determined by averaging the fold
change in transfection efficiency with the four normalized fold changes of EGFP
intensity. The proliferation score was determined similarly, by averaging the four
normalized fold changes of Hoechst intensity. Lastly, the viability score was determined
by averaging the two normalized fold changes in Resazurin intensity.

60
The highest and lowest transfection scoring compounds, up to ten each from each
plate, were selected as potential hits, from which the preliminary hits for the screen were
chosen, by inspection, based on transfection efficiency fold changes, transgene
expression fold changes, and Hoechst count fold change in the screen data and images.
Using Prism (GraphPad), one way ANOVA comparisons (Tukey’s post-test) were
performed between EGFP transgene expression fold changes of the hit compounds and
the plate vehicle controls. From these ANOVAs statistical significance of the priming
fold change effect over the vehicle was determined. An example of these statistical
analysis is demonstrated below in Figure 2.19, which shows how the fold changes for the
duplicates of both concentrations relate to the transfected vehicle control wells. The well
outline in yellow is Ketorolac, a nonsteroidal anti-inflammatory drug that showed
significant fold change increases at both 5 and 50 μM concentrations, while the well
outlined in red is Epigallocatechin gallate that showed significant fold change decrease in
transfection at both 5 and 50 μM concentrations as well.

Figure 2.19. One-way ANOVAs for statistical analysis of duplicate normalized
fold changes at 5 and 50μM
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2.3.15 Preliminary screen verification

For a preliminary verification of the significant increases and decreases in
transgene expression due to priming by the hit compounds identified by the screen, and to
explore whether additional information could be revealed by luciferase and bicinchoninic
acid (LUC/BCA) assay analysis of the screen lysate, compounds that were identified by
the screen to significantly affect transfection (three compounds that increase transfection,
and three compounds that decrease transfection) were tested in triplicate, in 48 well plate
format, and assessed by LUC/BCA assay. The same seeding density, priming
concentrations, and transfection conditions were used as in the screen, with volumes and
amounts scaled from the 96-well to 48-well format by the same factor as the change in
well growth surface area (0.32cm2 to 0.75cm2)
To quantify luciferase expression in cell lysate, 20 μL lysate samples were
pipetted into 100 μL aliquots of LAR reagent (Promega), vortexed for 10 seconds, and
measured by luminometer (Turner Designs). To quantify total protein concentration in
cell lysate by BCA assay, 50 μL of lysate samples were pipetted into 100 μL BCA
working reagent (50:1 BCA Reagent A:B) (Pierce), incubated for 30 minutes at 60 °C,
then measured for absorbance at 562nm by spectrophotometer. (Beckman Coulter) For
statistics, one way ANOVA’s with Tukey’s post-test were performed in Prism between
the tested conditions and the transfected vehicle control.
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2.4

Results and Discussion

Preliminary hit selection has been performed for four of the ten plates in the NCC
thus far, producing 38 hits from 285 NCC compounds. Listed in tables in Appendix A
are the top performers in terms of transfection score from the four NCC plates,
demonstrating priming increases and decreases at 5 both 50 μM (Tables A.1 through
A.4). To be clear, the entire NCC has been screened, data acquired and processed,
simply the hit selection has not been performed on data from six of the plates. The EGFP
Max/Min FC columns in Tables A.1 through A.4 denote the maximum or minimum
average EGFP fold change in transfection measurements with priming by the NCC
compound (in terms of plate reader and microscope image measurements, normalized by
either total cell count, or transfected cell count).
From these lists, compounds were grouped to identify drug classes that prime
transfection, identifying the 38 hits. The identified drug classes are represented in Table
2.1 below. This grouping was done by inspection, considering transgene expression and
transfection efficiency fold changes, Hoechst count fold changes, and literature
annotations of drugs class and known target receptors and pathways.

Table 2.1 Preliminary hit compound grouping by drug class.
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Statistical analysis of the hits in these drug classes was conducted by one way
ANOVAs versus transfected vehicle controls, with Tukey’s post-test. The observed
priming effects of the drug classes outlined in red in Table 2.1 above are discussed
below.

2.4.1

Antibiotics decrease PEI transfection of HEK293T cells

Figure 2.20 Antibiotic priming fold changes in transgene expression

Antibiotics appeared to generally knockdown transfection at the higher 50μM
concentration, holding true for different classes of antibiotic, bactericidal and
bacteriostatic, from cephalosporins, tetracyclines, to quinolones and fluoroquinolones.
The generality of the effect over several different antibiotic classes and higher
concentration at which the effect generally occurred seems to implicate a whole cell
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response to priming by antibiotics that knocks down transfection, rather than an
interaction with a very specific mechanism or pathway.
From the literature, it seems that the primary off target effects of antibiotics in
mammalian host cells are associated with mitochondria [100]. In the clinic, chronic
antibiotic treatments have been observed to cause ototoxicity, nephrotoxicity,
tendinopathy, and various other side effects [101]. The endosymbiotic theory which
describes the origin of mitochondria suggest that they were prokaryotes that became
incorporated into eukaryotes, so it is hypothesized that antibiotics target mitochondria
due to their similarities to bacteria, causing mitochondrial dysfunction and production of
reactive oxygen species. Induction of an oxidative stress response could explain the
knockdown effect on priming which antibiotics seem to have on transfection.

2.4.2

Stilbenoid and flavonoid antioxidants increase PEI transfection of HEK293T cells

Figure 2.21 Stilbenoid priming fold changes in transgene expression

Antioxidants were observed to have significant priming effects in increasing
transfection efficiency and transgene expression. Resveratrol is a natural phenol,
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specifically a stilbenoid, with antioxidant properties that can be found in the skin of
grapes [102]. There was toxicity associated with 50 μM and 5 μM resveratrol priming,
with 50 μM killing most cells in the well, however 5 μM toxicity was moderate, and
resulted in one of the highest overall increases to normalized EGFP expression observed
in the entire screening process, with a 3-fold increase in EGFP expression. Piceid is a
glucoside modification of resveratrol, which is also found naturally in plants. This
modification seems to blunt the effect of the priming increase on transfection compared
to resveratrol, while also causing less toxicity. Like antibiotics, antioxidants affect
mitochondria, however in a manner that generally protects or improves their function
[102]. Resveratrol has also been shown to rescue mitochondrial dysfunction and
modulate autophagy [103], which could have beneficial effects in the context of cytotoxic
effects of PEI transfection [39]. Rescued mitochondria could regain normal function,
while autophagy inhibits apoptosis.

Figure 2.22. Flavonoid priming fold changes in transgene expression
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Flavonoids are another class of plant-derived phenols [104], though the effects of
their priming upon transfection varied. Epigallocatechin gallate for instance, highly
knocked down transfection at both 5 and 50uM concentrations, yet Ipriflavone and Icariin
both increased transfection. If these antioxidants are each modulating transfection
through mitochondria and oxidative stress response [105], the variation in priming effects
may indicate that the cellular stress response to transfection can be modulated to increase
or decrease transfection, depending on the specific interactions with mitochondrial and
oxidative pathways each compound affects.

2.4.3

GABAA allosteric modulators increase PEI transfection of HEK293T cells

Figure 2.23. GABAA modulator priming fold changes in transgene expression

Diazepam and stiripentol both demonstrated a priming increase to transfection at
both 5 and 50uM. These drugs are both positive allosteric modulators of the GABAA
receptor found in neurons, however, they are thought to act on different subunits [106,
107]. The priming effects seen of these GABAA modulators is curious because
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neurotransmitter receptors are not typically expressed in most cell types. An interesting
possibility is that the proposed adrenal cortex origin of HEK293T cells [108] could imply
that the GABAA receptor, or at least some of the subunits, may be expressed in their cell
membrane. Another possibility is that these drugs are acting on the translocator protein,
also known as the peripheral benzodiazepine receptor, which is found in the membranes
of mitochondria, and thought to be involved in steroidogenesis, and redox regulation of
mitophagy [109, 110]. The latter would make sense in the context of priming the cellular
stress response to transfection that many of the other hits also imply.

2.4.4

Glucocorticoids increase PEI transfection of HEK293T cells

Figure 2.24. Glucocorticoid priming fold changes in transgene expression

Another group of compounds that was identified by the screen to prime and
increase transfection were glucocorticoids. Glucocorticoids are hormones which are
involved in the body’s stress response, activating the glucocorticoid receptor, which
translocates to the nucleus and acts as a transcription factor. It has been demonstrated
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previously in our lab that priming with glucocorticoids in human mesenchymal stem cells
increases transfection many fold [49]
The mechanism is not yet known, though it has been shown by preliminary data
to be associated with cytosolic glucocorticoid receptor, not the membrane glucocorticoid
receptor. Activated glucocorticoid receptors may play a role in priming transfection by
assisting internalization, nuclear transport, and nuclear import of transfection complexes.
Alternatively, or perhaps in conjunction, the glucocorticoid priming effects may be
occurring through modulation of mitochondria and autophagy [111, 112], which would
align with the possible mechanisms of priming other drug classes showed in the screen in
relation to the cellular stress response to transfection.

2.4.5

Preliminary Screen Verification

Six of the compounds identified by the screen to have priming effects at 5 μM
were re-tested for validation in triplicate. The validation experiment was seeded in a 48well plate format, and LUC/BCA assays were used to assess transfection. Three of these
compounds had been shown by the screen to enhance transfection, with the other three
shown by the screen to decrease transfection.
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Figure 2.25. Triplicate LUC/BCA verification of screen hits

From Figure 2.25, the relative levels of luciferase expression for all six
compounds, normalized by total protein, indicate that the screening process was able to
identify compounds that have priming effects on transfection. The yellow bars indicate
compounds that increased transfection in the screen, and did the same in this validation
experiment. The red bars indicate compounds that had decreased transfection in the
screen. In this validation experiment, one of the compounds, epigallocatechin gallate,
was consistent in knocking down transfection, but the other two compounds instead
showed an apparent increase in transfection within this validation experiment.
This result is not necessarily a conflict with the screen data, as luciferase
expression normalized by total protein does not providing the exact same information as
EGFP intensity measurements normalized by cell count. The relative transgene protein
expression levels should be consistent, but the observed differences could be attributable
to the different method of normalization, if total protein does not always necessarily
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correlate with total cell count. The differences could also simply be due to differences in
well plate format or un-optimized scaling of the various reagents to the larger well area.
The discrepancy should be investigated to prove whether the priming effects
observed of those drugs in the screen are real or a false positive. Some number of false
positives are inevitable in high throughput screening. In fact, it is encouraging that four
of the six identified in the screen to have priming effects, repeated those effects in the
verification experiment. A visual representation is given in Figure 2.26 below, which
shows the differences in EGFP expression in the priming conditions versus the
transfected vehicle control. EGCG consistently demonstrated consistency in knocking
down transfection, while resveratrol was one of the highest performers in the screen, and
continued to demonstrate high fold change enhancement of PEI transfection.
Corticosterone also repeated its enhancement of transfection, confirming its result in the
screen and also providing additional evidence of the reliability of glucocorticoid priming.
Noticeable in many of the compounds which had high fold change increases to
transfection were increased toxicity. The toxicity may be due to the priming compound’s
toxic effects, or amplification of the toxic effects of PEI, though another possibility is that
the production of mass quantities of EGFP transgene is causing cytotoxicity through
either EGFP toxicity [113] or the energy burden of transgene overexpression. An option
to test whether the toxicity is related to overexpression is to use a weaker promoter in the
pDNA sequence and/or less efficient formulation of PEI.
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Figure 2.26 LUC/BCA verification images showing relative EGFP expression
in cells primed with resveratrol, corticosterone, and EGCG versus transfected
vehicle control treatment.

2.5

Conclusion

Altogether, the literature review of grouped screen hit compounds implies that
many of the priming effects may be due to modulation of the cellular oxidative stress
response to PEI transfection, in particular mitochondrial dysfunction. PEI has been
shown to have cytotoxic effects through its accumulation in and interaction with
mitochondrial membranes [39]. Damage to mitochondria has been implicated in the
intracellular inflammatory and immune response [114, 115], and PEI has also been
shown to be an effective adjuvant to stimulate an immune response [116].
Typical cellular responses to mitochondrial damage are autophagy/mitophagy,
apoptosis, and necrosis. Apoptosis and autophagy are mutually inhibitory [117], with
apoptosis leading to cell death, while autophagy possibly serves a protective role in PEI
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cytotoxicity [118]. It seems plausible that antioxidants, in general, rescue the cell from
PEI-induced mitochondrial dysfunction, thus improving transfection, while priming with
other compounds, like antibiotics, may themselves induce mitochondrial dysfunction, or
perhaps promote autophagy or apoptosis.
Gene expression profiling has shown that there is differential expression in the
cellular oxidative stress response associated with successfully versus unsuccessfully PEI
transfected cells, through ATF3, IREB2 and other gene pathways [50-52]. The screen
data from this thesis support this claim, and suggest that modulating the cellular stress
response by priming with clinically approved compounds prior to PEI transfection can
have significant effects on overall transfection efficiency and transgene expression in
vitro.
Not only did the screen identify dozens of compounds that modulate PEI
transfection, the corroboration of the screen results with other work in the literature
indicates that the screen was successful in reinforcing and improving understanding of
pathways with which the total cellular response to nonviral gene delivery can be
modulated to improve transfection, and suggests specific classes of clinically approved
compounds which may be immediately useful in vitro and in vivo.

73
CHAPTER 3
Further Processing and Verification of the High Throughput Screen, and
Investigation of Priming Mechanisms Involving Mitochondria and Cellular Stress

3.1

Introduction

With the plenty of information gained from the screen, future work can proceed in
many directions, from completing the initial hit selection process from the data of six of
the ten NCC plates, to further analyzing the data already collected in the screen to extract
more information. A follow up high throughput LUC/BCA screen can be performed on
the lysate in cold storage, possibly with ATP quantification, to assess the initial imaging
screen’s performance, providing complementary transgene expression data, as well as an
additional cellular stress response measure. The screen image set can be further analyzed
by incorporating more sophisticated imaging algorithms to extract additional relevant
data. In the initial hit selection process, only EGFP expression and efficiency fold
changes and Hoechst count fold changes were considered as criteria, so Hoechst intensity
and Resazurin fold changes should also be analyzed in concert with the EGFP data to
understand the cell state at the time transfection was assessed, specifically cell viability
and extent of apoptotic and necrotic cell death. All of the screen measurements should be
incorporated into a more sophisticated hit selection strategy that incorporates the screen
data, literature information on candidate compound mechanisms and activity, and
previously identified differential gene expression profiles of PEI transfection in
HEK293T cells [50-52] into a network analysis approach to select priming candidates by
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a method that is sensitive to trends and patterns in the data, rather than relying on
inspection to catch the obvious trends. Additionally, the compounds which have been
identified by the screen thus far should be investigated in detail and incorporated as
priming adjuvants in new and effective gene delivery strategies.

3.2

Assessing screen performance

Preliminary analysis of the screen thus far shows that it has been successful in
achieving its purpose by identifying 38 compounds, and nine different drug classes, for
further investigation into priming of transfection (See Tables A.1-A.4 in Appendix A,
and Table 2.1 in Chapter 2). However, a true assessment of screen performance and the
hit selection methods used remains to be completed. In automated high throughput
screens of siRNA, a primary screen is generally conducted without replicates and
followed up with a confirmatory screen of at least triplicate [119]. In comparison, the
transfection priming screen of this thesis could be thought of as a primary screen in
duplicate. The addition of a duplicate to the primary screen should provide more
confidence in preliminary examination of the screened compounds, but it is not enough
replicates for the screen to be considered confirmatory [119].
The initial approach was to perform LUC/BCA validation of a few compounds of
interest that could then be immediately investigated if confirmed. Preliminary validation
of this type was performed that was generally confirmatory of the original hits, with two
of the six compounds showing an opposite effect from screen observation (Figure 2.25 in
Chapter 2), though as discussed previously, these differences could possibly be explained
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by an un-optimized switch from 96 well to 48 well format or the differences between
normalization by total cell count and by total protein. Even if all six compounds had
confirmed their effects observed in the screen, six compounds out of 725 is not a
sufficient sample size to assess the screen’s performance, and four out of six is actually
encouraging in providing evidence that the screen results are real.
The most complete way to assess the performance of this initial primary duplicate
screen would be to perform a total confirmatory screen, amounting to a repeat of the
screen in triplicate. However, the cost in materials and manual effort involved in the
initial screen make it unlikely that a total confirmatory screen will be performed without
automation of the liquid handling and imaging processes. An alternative would be to do
a partial confirmatory screen, that is, repeat the screen in triplicate for a subset of the
entire collection, possibly a plate or small number of plates in the collection, from which
the initial screen’s performance could be estimated.

3.3

High throughput LUC/BCA assays and ATP quantification of screen lysate for

imaging screen validation and complementary measures of transfection

An alternative to a total or partial confirmatory repeat screen could be high
throughput assays of LUC/BCA performed on the frozen lysate of the initial screen. This
alternative measure of transfection could be used to validate the initial fluorescence
imaging method. Compared to the initial LUC/BCA validation experiment (Chapter
2.4.5), there should be no issue with normalization or plate format, as the counts from the
initial screen can be used for normalization and there is no need to repeat the seeding,
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priming, and transfection processes, as the lysate is ready to test. The BCA assay will
also incorporate total protein into the dataset as a new relevant measure of the cell
response to transfection, a complementary measure of toxicity and/or viability, or an
alternative measure for normalization of the screen data.
The screen was conducted with a plasmid encoding an EGFPLuc fusion protein,
so LUC/BCA assays can be performed on the lysate, which has been stored at -80 °C.
High-throughput luciferase assay reagent kits are offered by several manufacturers,
which use a “glow” reagent formulation that reacts with luciferase for sustained
luminescence, allowing multiple wells to be measured over an extended period of time
without steep drop off in photons emitted due to long reaction times, which would cause
erroneous variation in apparent luciferase between wells [120].
Given access to a plate luminometer, the primary barrier to performing these
assays would be reagent cost. To perform LUC/BCA assays on the 40 plates in the
screen, at a luciferase assay reagent cost of at least fifty cents per sample (Steady-LUC
Firefly HTS Assay Kit, Biotium), material costs would be at least $3,000. With
“homemade” luciferase assay reagent, the total cost could be brought down to about
$1,000 total [120]. Also, a potential advantage of processing the screen lysate is the
opportunity to incorporate an ATP quantification assay along with the LUC/BCA
measurements. This is convenient because ATP quantification assays rely on the same
luminescent reaction that is used to quantify luciferase [121], as shown in Figure 3.1
below.
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Figure 3.1. Firefly luciferase catalyzes the luminescent reaction of d-luciferin [122].

In luciferase quantification, the kinetics of the luminescent reaction depend on the
concentration of firefly luciferase present in the lysate [120, 121]. In ATP quantification
by this same reaction, d-luciferin and luciferase are mixed at specific concentrations, and
a standard curve of luminescence versus ATP concentration is measured. The relative
luminescence of lysate samples treated with the same concentrations of d-luciferin and
luciferase can then be compared to the standard curve to determine ATP concentration
present in the lysate [120, 121]. ATP quantification can easily be multiplexed into the
LUC/BCA assay, simply requiring more of the same reagents used in LUC
quantification, as well as a portion of the sample lysate. Besides additional cost, the only
barrier to ATP quantification would be the ability of the ATP, LUC, and BCA assays to
perform accurately with smaller portions of the screen lysate sample volume
Measurement of ATP would be complementary to the Resazurin measurements
already acquired in the screen. Resazurin assays measure the overall redox state of the
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cell, while measuring ATP quantifies the available energy currency of the cell [123].
Both are markers for cell viability, however, they are related but not equivalent measures,
and analysis of both together might reveal subtle details of the manner in which
metabolic pathways are disturbed by PEI transfection cytotoxicity and possibly rescued
by some of the identified priming compounds (antioxidants, GABAA modulators,
glucocorticoids, etc., see Chapter 2.4)

3.4

Normalized Hoechst intensity measurements as a marker for cell cycle and cell

death

For the screen presented in Chapter 2, the Hoechst stain was used for total cell
enumeration, as both a measure of toxicity and means of normalization, but more
information can be extracted from the screen data through the normalized Hoechst
intensity measurements. While mean image intensity of a Hoechst stain image is
primarily dependent on cell count, normalizing Hoechst intensity by cell count will result
in a metric that reveals permeability of the cell and nuclear membranes as well as the
packing and integrity of chromatin [124, 125]. These parameters are markers for cell
cycle state, as well as apoptosis and necrosis [126]. Cell cycle and cell death pathways
can be associated with transfection efficiency, transgene expression, and metabolic
viability, and contribute to a more complete understanding of priming effects on
transfection through modulation of the total cellular response.

79
3.5

Phase contrast image analysis as a measurement of cell morphology

The screen image set can be further analyzed by incorporating more sophisticated
image processing algorithms to extract more relevant data. As mentioned previously
(Chapter 2.3.6), there is potential for the screen’s phase contrast images to be processed
by algorithms that can normalize the differences in illumination and shadow, after which,
total cell area can be calculated by thresholding algorithms. Normalization of cell area
by total cell count would provide a metric of average cell morphology, specifically cell
spreading, which could imply information of cell motility and extent of cell adhesion to
the well bottom substrate. Interpretation of cell spreading as a measurement of cell
motility and adhesion could allow cell spreading to serve as a proxy measurement of cell
membrane features related to environmental sensing and phagocytosis, such as actin
podia features and membrane ruffling, which preliminary work in our lab has indicated
may play a role in transfection complex internalization (data not shown).

3.6

Image segmentation to enable determination of EGFP expression of

subpopulations sorted by Hoechst stain

The image processing used in the screen described in Chapter 2 has been simple
in its approach. Total image mean fluorescence intensity was processed to average
fluorescence intensity per cell when normalized by cell count. A more nuanced approach
would be to actually measure fluorescence intensity for each cell, allowing for population
distributions to be determined. This approach would be enabled by cell segmentation,
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which is simply identification of boundaries for each cell in an image. Cell segmentation
image processing algorithms are fairly complex and were outside the initial scope of this
screen. Such algorithms achieve segmentation by fitting contours to image features, and
can be implemented by custom code, freeware such as ImageJ and CellProfiler, or
commercial image cytometry software.
For this screen, the phase image of each well would be the source image from
which the segmentation algorithm determines cell boundaries, so the previously
described preprocessing normalization of illumination and shadows would be necessary.
Segmented cell outlines can then be applied to the EGFP fluorescence images, from
which EGFP intensities of each cell could be measured and used to create a histogram
which captures the number of cells that are expressing EGFP at each observed intensity.
From these observed probability distributions of both EGFP and Hoechst intensities, 2D
histograms (scatter plots) could be created for each screened compound that allow for
association of EGFP expression with different subpopulations of cells sorted by Hoechst
stain. This type of information would be a more powerful data set from which to
interpret priming effects of the screened compounds on PEI transfection.

3.7

Interpreting the screen data by network analysis

From the initial screen, and potential follow-up LUC/BCA/ATP screen, for each
compound within the drug college, there will be a collection of measurements related to
the cellular response to priming and transfection, as well as measurements of transfection
efficiency and transgene expression. Beyond providing obvious candidates for
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immediate investigation as priming agents, the data can be analyzed as a whole to inform
our general understanding of transfection and the cellular response to transfection. For
instance, a relationship between transfection priming of certain compound classes and
mitochondrial dysfunction modulation is suggested by preliminary examination of the
data. A rigorous network analysis of the data set should support (or deny) this
correlation, while other relationships may become apparent. The network analysis should
incorporate normalized transfection measurements (EGFP, Luc), normalized cellular
response measurements (Hoechst, Resazurin, BCA, ATP, Phase area), keyword
annotations of known targets of the screened compounds (receptors, pathways,
organelles, etc.), and the gene expression profiles of successfully and unsuccessfully
transfected cell populations. The software of choice for analysis of high throughput
screen data is the R/Bioconductor statistical computing language and environment, which
has HTS packages generally tailored for siRNA HTS and DNA microarray data.
R/Bioconductor is the software which was used in previous FACS/microarray
experiments in our lab, which we would like to incorporate into the network analysis for
hit selection in any case, so R/Bioconductor network analysis and high throughput
screening packages would be a good place to start for this bioinformatics approach to hit
selection.
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3.8

Verification and investigation of priming mechanisms that involve modulation of

mitochondrial dysfunction and cellular stress response.

The majority of compounds identified as hits thus far from the screen seem to
possibly be modulating the mitochondrial dysfunction that is caused by PEI toxicity. To
verify the priming effects of these compounds, priming with these compounds should be
tested at a variety of concentrations, over a variety of time points pre- and posttransfection, to determine the breadth of the priming effect and optimum priming
condition. The timing information will be important in determining the window of time
cells can be primed by these compounds to have their effect on mitochondrial
dysfunction in a way that improves or decreases transfection. Optimized timing and
dosing parameters can be determined for each compound for use in the experiments
which follow that attempt to decipher the specific mechanisms of the observed priming
effects.
There are methods that mitochondria can be assayed directly. Mitochondrial
respirometry can be performed on isolated mitochondria to measure changes in oxygen
flux due to treatment of the priming agent [127]. Certain probes are also now able to
measure oxygen consumption in cultured cells (XF Extracellular Flux Analyzer, Seahorse
Bioscience) [128]. Also membrane potential can be monitored to examine how redox
potential across the mitochondrial membrane can change in response to PEI and priming
compounds. ATP is also a good indicator of mitochondrial viability, which can be
measured by luminescence [121].
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Another approach would be to mimic the gene expression profiling microarray
experiments performed in our lab previously[50-52], in terms of sorting the transfected
and un-transfected cell populations and assaying the subpopulations for differential gene
expression, in this case by qRT-PCR of genes that had been previously identified to be
related to cellular stress response, such as RAP1A, ATF3, IREB2, as well as genes whose
expression are known specific markers for mitochondrial dysfunction, autophagy,
apoptosis, and necrosis [39, 117, 129].
In addition to the qRT-PCR measures of gene expression, the transfected and
untransfected subpopulations should also be run through subcellular fractionation by
gradient centrifugation in order to quantify relative amounts of PEI and plasmid in the
various cell compartments. In subcellular fractionation, cells are gently lysed and
centrifuged through a density gradient to separate organelles by density. With optimized
subcellular fractionation protocols, nuclei, mitochondria, lysosomes, and cytoplasmic
fractions can be isolated. These separated fractions can then be measured for both
plasmid count and PEI concentration, with the plasmid count quantified by qRT-PCR,
and the PEI likely pre-labeled by conjugation to a fluorophore for fluorescence
quantification. These localization measurements in the various cellular compartments
should also be determined at various time points after priming and transfection for an
estimate of the transport mechanisms that are taking place for both the plasmid and PEI.
The change in PEI localization within the various compartments over time should be
informative, especially the amount of PEI which is found in mitochondria, in terms of the
mitochondrial dysfunction modulation priming hypothesis.
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Pull down methods and/or high resolution FRET imaging should also be used to
identify specific protein/protein and protein/DNA interactions that may be affecting the
behavior and interactions of complexes and cell machinery in response to priming.
siRNA could be useful for identifying such proteomic interactions as well by knocking
down specific genes/proteins and observing the resulting impact on priming. siRNA may
provide more precision in modulating a gene pathway than chemical inhibitors/activators.
From these experiments, screen hits should be verified by correlation of transfection fold
changes, cell viability measures, and specific changes in gene expression related to cell
stress response, autophagy, apoptosis, and necrosis, relative amounts of plasmid and PEI
in the various compartments of the cell, as well as specific protein/protein and
protein/DNA interactions, all in the context of successfully versus unsuccessfully
transfected cell populations. These experiments will hopefully illuminate the specific
mechanisms by which priming can rescue or mitigate mitochondrial dysfunction due to
PEI toxicity.

3.9

Final thoughts

Through high throughput screening of the NIH Clinical Collection, priming
compounds which impact nonviral gene delivery have been identified which reinforce
and improve our understanding of transfection and provide new tools for improving the
efficiency of gene transfer. With partial, preliminary hit selection from the collected
data, dozens of clinically approved priming compounds have potentially been identified.
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The remainder of the data should be assessed, possibly with more sophisticated image
processing techniques and hit selection approaches.
Grouping of the preliminary hits has implicated modulation of the cellular stress
response and mitochondrial dysfunction as important aspects of PEI transfection, so the
specific mechanisms by which these drug classes modulate mitochondria to affect
transfection should be investigated in detail, which will require a detailed understanding
of mitochondrial physiology, cellular stress pathways, and interplay between autophagy,
apoptotic, and necrotic cell death. The mechanistic relationships between PEI
transfection and different priming compounds on all of these processes will require
extensive literature review and experimentation. The apparent success of this study in
identifying clinical compounds that prime nonviral gene delivery could also warrant a
comprehensive automated screen of a larger compound library in combination with
different cell types, carriers, and nucleic acids, to confirm priming as a generally
applicable tool for nonviral gene delivery.
Overall, the identification of clinically approved priming compounds by this
screen is promising for the potential of their future implementation as adjuvants of
nonviral gene delivery in vivo and eventually in clinical gene therapy applications. Even
the clinical compounds that were found to decrease transfection are also possibly
important to understand as potential contraindications for patients who are depending on
expression of a therapeutic gene through nonviral gene delivery.
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APPENDIX A: Tables listing NCC Compounds that prime transfection





FC: Fold-change
EGFP Max/Min FC: Maximum or minimum fold change in EGFP expression or
transfection efficiency, plate reader or image measurement, normalized by total
cell count or transfected cell count.
Bolded drugs were selected as hits from these lists by fold change, toxicity, and
drug grouping based on literature annotations of each drugs known mechanisms
of action.

Table A.1

NCC Compounds that increase transfection at 50 μm

EGFP Max FC
1.35

Hoechst Count FC
1.05

Drug Name
NICORANDIL

Grouped Drug Class

1.37

0.68

GABA

1.32

0.68

DIAZEPAM
ALOSETRON

1.23

1.02

NORNICOTINE

1.67

0.7
0.65

EPIRIZOLE
VARDENAFIL

NSAID

1.32
1.77

0.72

GABA

1.4

0.74

STIRIPENTOL
TOCAINIDE

1.47

0.76

BENACTYZINE

1.55

0.6

2-PYRIDYLETHYLAMINE

1.41

0.78

1.63

0.68

ICARIIN
CETRAXATE

1.69

0.49

SR 57227A

1.95

0.81

KETOROLAC

NSAID

1.42

0.59

PROTON PUMP INHIBITOR

2.16

0.39

PANTOPRAZOLE
LOFEXIDINE

2.26

0.55

ZARDAVERINE

1.73

0.43

ISRADIPINE

2.27

0.4

1.72

0.46

INDOMETACIN
DIHYDREXIDINE

2.22

0.32

CLONIDINE

2.32

0.52

2.09

0.48

FLUCYTOSINE
ROSIGLITAZONE

3.63

0.55

TRANILAST

2.63

0.69

1.75

0.49

PICEID
RUFLOXACIN

2.11

0.44

FENOLDOPAM

2.07

0.51

NATEGLINIDE

FLAVONOID

NSAID

ANTIFUNGAL

STILBENOID
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Table A.2

NCC Compounds that increase transfection at 5 μM

EGFP Max FC
1.39

Hoechst Count FC
0.71

Drug Name

Grouped Drug Class

VORICONAZOLE

ANTIFUNGAL

1.30

0.84

1.53

DIAZEPAM
MEGESTROL ACETATE

GABA

0.74

1.57

0.65

ITRACONAZOLE

ANTIFUNGAL

1.39

0.83

NSAID

1.50

0.65

PIROXICAM
TRYPTOLINE

1.31

0.63

AM251

1.61

0.48

HALOPERIDOL

1.31

0.62

1.36

0.60

STIRIPENTOL
OXYPHENONIUM BROMIDE

1.60

0.60

METHOXYTRYPTAMINE

1.43

0.67

1.44

0.71

MESALAZINE
SELEGILINE

1.59

0.56

ITOPRIDE

1.30

0.55

QUETIAPINE

1.24

0.66

CYCLOSERINE

1.55

0.60

ANTIHISTAMINE

1.21

0.63

DEXCHLORPHENIRAMINE
LEVORPHANOL

1.33

0.86

ANTIHISTAMINE

1.55

0.60

DEXBROMPHENIRAMINE
LOFEXIDINE

1.54

0.96

CALCITRIOL

1.59

0.72

1.53

0.73

OXAPROZIN
REMACEMIDE

1.71

0.54

LOFEPRAMINE

1.52

0.67

TROXIPIDE

1.87

0.49

MEDROXYPROGESTERONE

HORMONE

1.52

0.69

OMEPRAZOLE

PROTON PUMP INHIBITOR

1.72

0.60

CYPROHEPTADINE

ANTIHISTAMINE

1.49

0.70

BECLOMETASONE

GLUCOCORTICOID

1.52

0.86

ROLITETRACYCLINE

ANTIBIOTIC

1.51

0.65

CORTICOSTERONE

GLUCOCORTICOID

2.01

0.45

GLUCOCORTICOID

1.57

0.64

DESOXIMETASONE
2-CHLOROADENOSINE

3.04

0.55
0.54

RESVERATROL
MEPIVACAINE

STILBENOID

1.78
4.28

0.36

IPRIFLAVONE

FLAVONOID

GABA

NSAID

NSAID
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Table A.3

NCC Compounds that decrease transfection at 50 μM

EGFP Min FC
0.36

Hoechst Count FC
1.67

Drug Name
HYPEROSIDE

Grouped Drug Class
FLAVONOID

0.80

1.14
1.16

PARECOXIB
VORICONAZOLE

NSAID

0.74
0.81

1.02

ANTIBIOTIC

0.83

1.09

PAZUFLOXACIN
BUPROPION

0.63

1.24

TOSUFLOXACIN

ANTIBIOTIC

0.71

1.28

CEFACLOR

ANTIBIOTIC

0.61

1.15

CLARITHROMYCIN

ANTIBIOTIC

0.75

1.35

FLAVONOID

0.57

0.83

RUTIN
SKF 83566

0.63

0.49

ETOMOXIR

0.74

0.61

TICLOPIDINE

0.75

0.93

0.00

0.80

FLAVONOID

0.03

1.34

TACRINE
EPIGALLOCATECHIN
GALLATE
CEFDINIR

0.02

1.45

CEFIXIME

ANTIBIOTIC

0.15

1.10

TAXIFOLIN

FLAVONOID

0.06

1.42

ROLITETRACYCLINE

ANTIBIOTIC

Table A.4

ANTIBIOTIC

NCC Compounds that decrease transfection at 5 μM

EGFP Min FC

Hoechst Count FC

Drug Name

0.58
0.89
0.94
0.68
0.93
0.91
0.85
0.87
0.89
0.86

0.95
0.93
0.92
0.69
0.89
0.90
0.94
0.96
0.90
0.94

0.08

1.37

0.82
0.78
0.61
0.63
0.77

0.90
0.89
1.36
1.36
0.76

PRAVASTATIN
LAMOTRIGINE
TOSUFLOXACIN
DIPHENOXYLATE
TERBINAFINE
CLARITHROMYCIN
SDM25N
LOXAPINE
NAPROXEN
MALTOL
EPIGALLOCATECHIN
GALLATE
TRIFLUOPERAZINE
NALBUPHINE
CEFIXIME
ISOQUERCETIN
5-(NONYLOXY)TRYPTAMINE

Grouped Drug Class

ANTIBIOTIC
ANTIFUNGAL
ANTIBIOTIC

NSAID
FLAVANOID

ANTIBIOTIC
FLAVONOID
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APPENDIX B: ImageJ macros used for image processing

Image intensity and local maxima detection macro:
start=1;
imagesperwell=3;
end=288;
path="C:\\Users\\anguyen2\\Desktop\\AN-15-40\\10\\5uM\\2\\";
i=1;
count=0;
for(x=start+1; x<=end; x=x+3)
{
//gfp images
open(path+"image"+x+".tif");
run("Measure");
run("Enhance Local Contrast (CLAHE)", "blocksize=127 histogram=256
maximum=3 mask=*None* fast_(less_accurate)");
run("Subtract Background...", "rolling=10");
run("Find Maxima...", "noise=10 output=Count");
selectWindow("image"+x+".tif");
close();
}
for(x=start+2; x<=end; x=x+3)
{
//hoechst images
open(path+"image"+x+".tif");
run("Measure");
run("Subtract Background...", "rolling=10");
run("Find Maxima...", "noise=10 output=Count");
selectWindow("image"+x+".tif");
close();
}
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Plate montage creation macro:

start=1;
imagesperwell=3;
end=288;
path="C:\\Users\\anguyen2\\Desktop\\AN-15-40\\10\\5uM\\2\\";
i=1;
count=0;

//phase
for(x=start; x<=end; x=x+3)
{
open(path+"image"+x+".tif");
}
run("Images to Stack", "name=Stack title=[] use keep");
run("Make Montage...", "columns=8 rows=12 scale=1 first=1 last=96 increment=1
border=10 font=12");
for(x=start; x<=end; x=x+3)
{
selectWindow("image"+x+".tif");
close();
}
selectWindow("Montage");
run("Rotate 90 Degrees Left");
run("Flip Vertically");
waitForUser;
//gfp
for(x=start+1; x<=end; x=x+3)
{
open(path+"image"+x+".tif");
}
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run("Images to Stack", "name=Stack title=[] use keep");
run("Make Montage...", "columns=8 rows=12 scale=1 first=1 last=96 increment=1
border=10 font=12");
for(x=start+1; x<=end; x=x+3)
{
selectWindow("image"+x+".tif");
close();
}
selectWindow("Montage");
run("Rotate 90 Degrees Left");
run("Flip Vertically");
waitForUser;
//hoechst
for(x=start+2; x<=end; x=x+3)
{
open(path+"image"+x+".tif");
}
run("Images to Stack", "name=Stack title=[] use keep");
run("Make Montage...", "columns=8 rows=12 scale=1 first=1 last=96 increment=1
border=10 font=12");
for(x=start+2; x<=end; x=x+3)
{
selectWindow("image"+x+".tif");
close();
}
selectWindow("Montage");
run("Rotate 90 Degrees Left");
run("Flip Vertically");

